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1 Abstract 
The skin is a major physical and immunological barrier to the environment, and thus, percutaneous 
delivery of drugs or active pharmaceutical molecules (APIs) faces a unique set of hurdles. The efficacy 
of these active ingredients is governed by their release into the underlying tissue, especially when 
administered topically. However, the factors driving penetration in dermal and transdermal delivery 
systems remain poorly understood, and robust methods, models, and controls are important to bridge 
this gap in knowledge. The aim of this study is to understand what influences skin penetration and to 
identify reliable human skin surrogates for in vitro and ex vivo testing. The lipophilic characteristics of 
active ingredients determine its penetration, and thus play an important role in enabling access to the 
target-site. Thus, in addition to vertical penetration, the skin allows a lateral diffusion of active 
molecules and maintains an intra-donor equilibrium within the stratum corneum, viable epidermis, 
and dermis.  
To test this effect, three surrogate systems have been used, the in vitro artificial Strat-M® membrane, 
ex vivo porcine split-skin, and human split-skin. The reproducibility and validity of these models was 
tested using hydrophilic caffeine and lipophilic LIP1 as model drugs, which have similar molecular 
weights, in various formulations. The uptake kinetics were monitored and quantified using a Franz 
Diffusion Cell and microdialysis, followed by high-performance liquid chromatography to qualify and 
quantify the active ingredient. Appropriate surrogate models were identified and the conditions 
required to perform penetration experiments that are most reflective of in vivo conditions were 
optimized. The findings show that the potential barrier and reservoir function of the different skin 
layers, donor-specific intra-skin equilibrium with inter-skin difference, and lateral diffusion are 
significant contributors to the overall penetration ability. The penetration models developed and 
described herewith help to understand the conditions necessary for the penetration of molecules of 
interest and standardize the model to be chosen for a specific analytical case. This could in turn lower 
the attrition rate of active compounds in in vivo trials.  
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2 Zusammenfassung 
Die Haut, als wichtige physikalische und immunologische Barriere zum Schutz vor Umwelteinflüssen, 
macht, aufgrund ihrer Abwehrmechanismen, die perkutane Penetration von aktiven Wirkstoffen und 
Arzneimitteln zu einer Herausforderung. Bei der Entwicklung von Wirkstoffen ist eine kontrollierte 
Penetration durch eine topische Applikation für die Funktionalität dieser entscheidend. Bis heute sind 
Faktoren, die die dermale und transdermale Penetration beeinflussen, wenig bekannt, weshalb die 
Entwicklung von robusten Modellen und Methoden für spezifische Untersuchungen umso 
entscheidender ist. Das Ziel dieser Arbeit war es, mithilfe eines erlangten Verständnisses für 
Penetrationsvorgänge, geeignete Menschen Hautmodelle für in vitro und ex vivo Tests zu entwickeln. 
Die Lipophilie von Wirkstoffen hat einen entscheidenden Einfluss auf die Penetrationsfähigkeit und 
ihren Transport an den Wirkungsort. Deshalb wurde das spenderspezifische Gleichgewicht hinsichtlich 
der Verteilung aktiver Moleküle in Stratum Corneum, Epidermis und Dermis untersucht. Aktive 
Moleküle können in der Haut sowohl vertikal penetrieren als auch lateral diffundieren.  
Um diesen Effekt nachzuweisen, wurden mehrere Hautersatzmodelle verwendet, zum einen die 
künstliche Strat-M® Membran für in vitro Tests und zum anderen Spalthaut vom Menschen sowie vom 
Schwein für ex vivo Tests. Die Reproduzierbarkeit und Validität dieser Modelle wurde unter 
Verwendung zweier Modellwirkstoffe mit identischem Molekulargewicht, hydrophiles Koffein und 
lipophiles LIP1, getestet. Penetrationsversuche dienten der Untersuchung des Einflusses der 
Formulierung auf die Penetrationseigenschaften aktiver Moleküle. Die Aufnahmekinetik wurde mittels 
Franz-Diffusions-Zelle und Mikrodialyse bestimmt. Zur Qualifizierung und Quantifizierung der 
Wirkstoffe wurde die Hochleistungsflüssigchromatographie (HPLC) herangezogen. Anschließend 
erfolgte die Identifizierung geeigneter Ersatzmodelle für menschliche Haut und die Optimierung der 
Bedingungen für die Durchführung von Penetrationsexperimenten, die die in vivo Bedingungen am 
besten widerspiegeln. Dabei wurden eine Barriere- und Reservoir-Funktion der verschiedenen 
Hautschichten, ein spenderspezifisches Intra-Haut-Gleichgewicht und eine laterale Diffusion, als 
signifikanter Beitrag zur gesamten Penetration bestimmt. Die entwickelten Penetrationsmodelle 
dienen dem Verständnis erforderlicher Bedingungen für das gezielte Eindringen von Molekülen in die 
Haut und schaffen die Voraussetzung für eine standardisierte Durchführung von Versuchen. Die 
Berücksichtigung der erarbeiteten Ergebnisse und Erkenntnisse können dazu beitragen, die Ausfallrate 
von Wirkstoffen in in vivo Versuchen zu senken. 
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3 Aim of the project 
 
During the course of this doctorate project, the following questions were investigated: 
 
• How does the formulation, formulation volume, active concentration, temperature, and 
receptor fluid influence the skin penetration of an API? 
 
• Are in vitro and ex vivo human skin surrogates suitable systems to compare the influences on 
percutaneous penetration using a Franz Diffusion Cell setup? 
 
• How does the stratum corneum, epidermis, and dermis contribute to the barrier function of 
the skin and what is the effect of hydrophilic and lipophilic molecules on the diffusion and 
penetration in those layers? 
 
• How is the saturation of an active ingredient in the different skin layers defined and is an 
individual donor dependent saturation a limiting factor for penetration? 
 
• Does the skin enable lateral penetration and diffusion of hydrophilic and lipophilic APIs inside 
the epidermis and dermis and is it quantitatively important for calculating the total 
penetration for a finite and infinite dosage? 
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4 Introduction 
The skin is the biggest human organ and accounts for 10 % of the body weight. With approximately 
2 m² of surface area, the skin covers the entire body like an envelope and serves as the body’s primary 
defense [1]. Owing to its complex multilayered structure, the skin possesses mechanical, regulatory, 
and sensation functions. The mechanical function provides both, a morphological flexible support 
apparatus with its connective and supporting tissue. It also serves as a mechanical barrier, protecting 
the body from irradiation exposure and exogenous environmental stresses and therefore forming a 
barrier that ensures decreased permeability for endogenous substrates and controlled permeability 
for primary gases and water loss. Additionally, the skin is an optimized barrier against exogenous 
substances like environmental pollutants and microorganisms. As an organ its regulatory functions 
include the control of oxidants, microbiome, immune response, metabolite synthesis and body 
temperature via sweat and water loss. The skin contains an extensive network of nerve cells which 
respond to environmental changes with a sensory function and is sensitive to heat, cold, touch, and 
pain. 
To ensure site-specific penetration of an active pharmaceutical ingredient (API), a fundamental 
knowledge of skin morphology and physiology is required along with an understanding of its influence 
on API permeability. Because the skin is a complex and dynamic system, investigating these influences 
is indispensable for understanding and improving permeation and API delivery. [2, 3]  
Until recent years, the skin has been primarily regarded as a protective cover of the body. Due to the 
difficulties overcoming this barrier, only a limited number of drugs are administered transdermally [4]. 
Exploitation of this route of administration is particularly important for therapeutic, diagnostic, 
prophylactic, and cosmetic applications [5]. Delivery of drugs in close proximity to the afflicted site 
inside the skin has advantages in terms of clinical treatment of disorders such as acne and cutaneous 
inflammatory diseases, wound healing, and inflammation [2, 6, 7]. Dependent on their mechanism of 
action, topically applied active ingredients have varying target-sites. Dermal drug delivery focuses on 
the site-specific localization of active ingredients in the skin to ensure controlled or prolonged drug 
delivery and systemic drug exposure. Site-specific drug delivery and a localized target in various skin 
layers adds complexity to the development of dermal drug delivery systems. Transdermal therapy aims 
at delivery to the systemic blood circulation and is an alternative to oral and intravenous drug delivery, 
if a significant concentration of API is ensured. [8, 9] 
 
 Morphology of the skin 
Progressing inward, the human skin consists of three main layers: the epidermis, dermis, and subcutis.  
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Figure 1: Morphology of the skin with its epidermis, dermis, and subcutis layer. [10] 
 
Epidermis 
The epidermis with its self-renewing properties consists of four distinctive layers and is divided into 
the viable epidermis and a non-viable dead horn layer (stratum corneum (SC)). Keratinocytes account 
for 95 % of the main cell type of the epidermis. These cells differentiate to form multiple layers [11, 
12]. Keratinocytes migrate from the stratum basale to the stratum spinosum and stratum granulosum 
layer, which make up the viable epidermis, culminating into the final differentiation product, the SC; 
this process takes approximately 30 days [13]. The epidermis derives from the surface ectoderm, which 
becomes the embryonic epidermal basal single layer after epidermal commitment [14]. Thus, a single 
layer of ectoderm is formed at E9.5, and at E15.5 the proliferation is almost completely confined to 
the basal layer [15]. During this stage, a protective layer is already excised, the periderm, which 
protects the developing skin from constant exposure and from bacterial and environmental insults 
[15]. After the epidermis has fully stratified in the first few weeks and its differentiation into the five 
strata is completed, the protective periderm is shed [15, 16].  
The multilayered epithelium contains a proliferating basal layer and a suprabasal layer in which the 
keratinocytes differentiate but no longer have the proliferation function [17]. The stratum basale is a 
single cell matrix layer that is attached to the basement membrane via hemidesmosomes and is 
considered a stem cell layer. Desmosomes are intercellular junctions of epithelia specialized for strong 
adhesion directly from cell to cell, in contrast to hemidesmosomes, which form adhesions between 
cells and the basement membrane [18]. In the basal layer, the epidermal stem cells proliferate, commit 
to differentiation, and migrate towards the environmental interface of the epidermis. During this stage 
of differentiation, the keratinocyte changes its horizontal axis formation to a volume richer, vertically, 
polygonal form, the stratum spinosum stage. This layer is formed by two to five prickle cell layers 
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attached via desmosomes [13]. During this stage, the early differentiation marker proteins such as 
Keratin 1 and 10 are expressed by the keratinocytes [3]. The stratum granulosum contains one to three 
grain layers. In this stage of differentiation, the cells flatten out and the keratinocytes contain a high 
number of keratohyalin and membranous lamellar granules, referred to as lamellar bodies. These 
lamellar bodies, which are assembled in the Golgi, are tubular or ovoid-shaped, membrane-bound 
organelles. They synthesize and store glucosylceramides, cholesterin, free fatty acids, and 
phospholipids like sphingomyelin, which are precursors of SC lipids [19, 20]. Additionally, the lamellar 
bodies are responsible for the packing of antimicrobial peptides, proteins, protein-degrading enzymes 
and protease inhibitors as well as for corneocyte desquamation [3]. At the stratum granulosum-
corneum junction, the keratinocytes extrude those lipid precursors from the intracellular space into 
the intercellular lipid space via exocytosis. During this stage, the cell dehydrates and loosens its 
nucleus, followed by cornification into a corneocyte and SC formation followed by desquamation [21]. 
Corneocytes adopt a characteristic flattened, dead cell dimension and are oriented parallel to the skin 
surface that interacts closely with the surrounding grid [11, 22]. Those corneocytes are the building 
blocks of the skin barrier and are formed by a unique process of programmed cell death associated 
with the expression of specific genes that control multiple steps of this pyroptosis program. The SC, 
which is typically 10-20 µm thick, comprises 10-30 layers of corneocytes, which are filled with water 
and microfibrillar keratin filaments [7]. With a width of 30 µm and height of 1 µm, a corneocyte is 
embedded in a complex continuous, multilamellar, lipid-enriched matrix. These lipids are 
enzymatically processed from their precursor form to their final state. Free fatty acids, cholesterol, and 
ceramides are the main lipid classes inside the epidermis, whereas ceramides account for about 50 % 
of the SC lipids [12, 13]. The ceramide family comprises at least seven subfractions, they are important 
not only due to their predominance but also their long-chain and amphiphilic structures and are crucial 
for the formation and maintenance of the cutaneous permeability barrier of the skin [23]. Ceramides 
are important as bioactive metabolites involved in cellular signaling, proliferation, differentiation, and 
apoptosis in the human epidermis and they are essential components of the plasma membrane [24]. 
Additionally, the SC contains other lipids such as triglycerides, wax esters, and squalenes [21]. This 
intercellular lipid space constitutes about 15 % of the SC dry weight with about 20 % water content [3, 
25]. The SC provides a unique lipid matrix structural basis, which leads to an extraordinary low water 
and antimicrobial permeability. The corneocytes provide mechanical UV protection [3]. They build a 
cornified envelope together with a densely crosslinked layer of late differentiation marker proteins 
such as filaggrin, loricrin, and involucrin and are, along with γ-transglutaminase, responsible for the 
cornification process [13]. During cornification, the intracellular organelles within the epidermis are 
replaced by a compact proteinaceous cytoskeleton. This is followed by the formation of the cornified 
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envelope due to cross-linking of proteins at the cell periphery and the linkage of the corneocytes into 
a functional biologically dead structure [26]. The viable epidermis, which is 50-100 μm thick, is a non-
vascular tissue with sensory nerve endings and acts as the first line of immune defense [12, 27]. In 
addition to the keratinocytes, this epithelial tissue contains other metabolically active cells such as 
Merkel cells, melanocytes, and Langerhans cells [28]. Merkel cells are approximately 10 µm in 
diameter and are located in the basal layer, more or less frequent depended on the body region, and 
differentiate from the ectoderm [29]. Controversially discussed, they are associated with sensory 
nerve ending function and are assumed to play a role in response to light and touch stimuli [30, 31]. 
Melanocytes, which are exclusively localized to the basal layer, account for about 10 % of the basal 
layer cells and derive from the neural crest ectoderm [32]. They share many characteristics with 
dendritic cells and their dendrites interact with other layers of the epidermis [27]. Their main purpose 
is the production of three melanin types: eumelanin, pheomelanin, and neuromelanin. Melanin is 
transported to the nearby keratinocytes to induce pigmentation, which serves as protection against 
UV radiation [31]. Besides this, melanocytes play a role in the immune system and immune response. 
However, the primary skin immune response is linked to Langerhans cells [7]. They are present in all 
viable epidermis layers, but most prominently in the stratum spinosum. Langerhans cells share 
similarities with both dendritic cells and tissue macrophages, are specialized in antigen presentation 
and are involved in immune homeostasis and the uptake of apoptotic bodies [31]. Overall, the 
epidermis is important for a reservoir function and acts as a main barrier against pathogens of the skin. 
The epidermal differentiation process is linked and regulated inter alia by the concentration of 
extracellular Calcium and by its acidic cornified envelope, which regulates the homeostasis of the 
epidermal permeability barrier [3]. The acidic environment (pH 4-6) protects the body by maintaining 
the natural skin microflora and prohibits the growth of certain pathogenic microorganisms [12]. Many 
skin enzymes, such as β-glucocerebrosidase and sphingomyelinase, are linked to the SC lipid 
homeostasis and function optimally under acidic conditions. [33, 34] 
 
Dermis 
The dermis is located under the epidermis, has a thickness of 1-2 mm, and is divided into the upper 
papillary layer and lower denser reticular layer [7]. Those layers are derived from the dermatome 
region of the mesoderm [35]. The dermis consists of extracellular matrix, which is made up of 
intertwined elastic fibers and collagen proteins that comprise the bulk of the skin and yields an elastic 
and tight tissue [12]. There are different collagen types inside the skin, and type I and II account for 
approximately 75 % of the dermis dry weight [2]. Besides the extracellular matrix, this connective 
tissue contains sensory nerve endings, blood vessels, and lymphatic vessels [12, 36]. Different cell 
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types including immune cell systems are embedded in the dermis. The most prominent cell type in the 
dermis is the fibroblast, which accounts for the synthesis of the extracellular matrix and collagen and 
is derived from the paraxial mesoderm [13, 37]. Dendritic cells and their subsets are involved in 
regulation and initiation of many immunologic responses and play a role in dermal inflammation, 
wound healing, skin sensitization, tissue remodeling, and activate the humoral immune response [7, 
36]. The dermis also includes hair follicles, sweat glands, and sebum glands, which increases the 
surface area depending on the body region [38]. They invaginate the skin´s epidermis and dermis and 
open directly into the skin surface and to the environment [39]. Penetration via these pilosebaceous 
units is known as the appendage route, and they have been shown to have a complex, dynamical 
structure and contribute to the regulation of biochemical, immunological, and metabolic activities [7]. 
 
Subcutis 
The innermost layer of the skin is the subcutaneous layer or hypodermis, which is derived from the 
dermatome region of the mesoderm [35]. This layer encloses fibroblasts, adipose cells, and 
macrophages. It is composed of adipose tissue, fascia, as well as larger lymphatic- and blood vessels 
[12]. The adipose tissue, made up of adipocytes or fat cells is mainly used for fat storage and acts as 
an insulator to regulate body temperature [40]. It is a loose connective tissue and forms in entirety the 
panniculus adiposus. The fascia surround and separate muscles, bones, and joint capsules and are an 
assembly of fibrous, tough connective tissues [7]. The delivery of active ingredients inside the 
hypodermis and therefore to the muscle and fat tissue is a complex process; thus, direct penetration 
and systemic blood circulation supply contributes to the muscular deposition [41]. Drug lipophilicity, 
molecular size, and protein binding ability influence the hypodermis portioning as well as the dermal 
blood flow in local tissues [42]. 
 
 Drug delivery via the skin 
Due to the biological and metabolic activity of the skin, an understanding of how substances get into 
and through each skin layer is essential for a target-site activity. Most APIs penetrate by passive 
diffusion across the skin, whereas active transport plays a limited role [38]. There are multiple 
biotransformations such as oxidation, reduction, hydrolysis, and conjugation that occur inside the skin. 
These processes have minor influences on penetration; for example, steroids (testosterone and 
estradiol) are converted to an active form while penetrating the skin [43]. Therefore, the bioavailability 
of topically applied substances might be influenced by biotransformation, enzyme activity, or transport 
mechanisms [13]. 
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As described by the Organization for Economic Co-operation and Development (OECD), dermal 
absorption is the global term that describes the transport of molecules from the surface of the skin in 
the systemic blood circulation divided into permeation, penetration, and resorption [44]. Permeation 
is the diffusion movement through pores or the entry of a substance into a particular layer such as the 
entrance into the SC. However, penetration is a process of translocating into deeper layers and going 
from one layer into a second layer that is functionally and structurally different from the first one. 
Resorption is the uptake of molecules in the systemic circulation and therefore systemic absorption, 
which is mostly referred to according by Environmental Health Criteria (EHC) 235 from the World 
health organization (WHO) as transdermal penetration [45]. The rate and efficiency of API absorption 
and penetration into the skin is linked to multiple aspects: the ability to pass through the SC, the 
thickness of the SC, pathological changes in the skin, the number and size of hair follicles, age, and 
blood circulation [21]. The anatomical location of the penetration site has a strong contribution to its 
permeability. Follicular dense regions like the forehead, ears, and cheeks show for certain substances 
an increased penetration rate compared to the forearm [21]. Despite a thicker SC, the penetration rate 
at the palms is similar to that at the forearm [21]. Furthermore, when considering the permeability of 
diseased skin, the influence of the altered barrier function needs to be given special consideration [46]. 
In general, there are three main potential routes for drug delivery into or across the skin: (1) The intra- 
or transcellular route through the corneo- and keratinocytes. Via this route, drugs pass through both 
the lipid matrix and cells. (2) The intercellular pathway, where the drug needs to pass through the lipid 
matrix and the intercellular space between the cells of the skin [47]. (3) Through the transappendageal- 
or follicle route, the drug penetrates through the hair shaft, sebaceous glands, or sweat glands to get 
into the skin [48]. The intercellular route is the most common way for drug penetration across the 
whole skin and involves several steps: (a) dissolution and release from the formulation, (b) partitioning 
into the SC, (c) diffusion across the SC and the lipid domains, (d) partitioning from the SC into the more 
aqueous viable epidermis part, (e) diffusion through the viable epidermis over the tight junctions into 
the dermis part, and (f) drug absorption and uptake in the local target tissue site and vessels, which 
leads to systemic circulation [49]. 
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Figure 2: The structure of skin illustrating different penetration pathways. The skin is organized into multiple layers, which 
contain different cell types. Skin penetration occurs through the follicular (1), intracellular (2), or intercellular (3) pathway. 
[50] 
 
Penetration inside the skin 
The pathway for topical penetration is influenced by potential absorption from the skin surface into 
the lipophilic SC followed by a subsequent permeation through the more aqueous, non-vascular viable 
epidermis into the perfused, aqueous dermis [38]. The API in a formulation aims to achieve equilibrium 
by redistributing itself into the skin. This partitioning of the molecule to redistribute the concentration 
gradient, formed when the API is applied to the skin, combined with the affinity of the penetrating API 
to lipophilic or hydrophilic environments is the driving force for penetration into skin [38]. The API 
diffuses within the formulation to the formulation-skin interface and partitions into the skin. There, it 
diffuses through the lipophilic SC, thereafter partitioning and diffusing into and through the hydrophilic 
viable part of the epidermis. From the epidermis it partitions into and diffuses through the dermis 
before partitioning into the systemic circulation [51]. Lipophilic molecules cross the SC, which is 
described as the primary penetration barrier and will penetrate slower through the hydrophilic viable 
epidermis and dermis. The passive penetration of active ingredients inside the skin can be grouped 
into (1) molecular diffusion, (2) partitioning, (3) metabolism and phase change, and (4) binding and 
absorption [52]. This passive penetration process has been described as Fick’s first law of diffusion in 
1855. Fick´s law describes the passive diffusion movement of unbound molecules, towards equilibrium 
in response to a concentration gradient [53]. 
 
(1) 
(2) 
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𝐽 = 𝐾𝑝 ×  ∆𝐶 
𝐾𝑝 =
 𝑃 ×  𝐷
ℎ
 
 
The molecule penetration rate is expressed as the flux (J), under steady-state conditions, with the 
concentration gradient across the membrane (ΔC), and the permeability coefficient (Kp). Kp is 
expressed by the partition coefficient (P), the diffusion coefficient (D), and the diffusion path length 
(h). 
 
Figure 3: Model of the absorption across the skin barrier. 1 = Penetration phase: passive diffusion into the lipophilic SC; 2 = 
permeation phase: the transport through the more aqueous, avascular, viable epidermis to the highly perfused dermis; 3 = 
resorption phase into the microcirculation and further to the systemic circulation or deeper into the tissue (regional 
penetration); (4) = affinity of the penetrant for the SC or the dermis (reservoir formation). [38] 
 
Epidermis 
The main barrier function of the skin is linked to the epidermal layer. Generally, small hydrophilic 
molecules overcome this barrier via the transcellular route and small lipophilic molecules via the 
intercellular route [12]. Compared to a physiological pH of 7.4, which is present in the blood stream, 
the pH of the skin varies within a range of pH 4.5 to 5.5 and is therefore slightly acidic and regulated 
via endogenous factors, e.g. skin moisture, sebum, nutrients, and age [54]. This acidic environment is 
crucial for the control of the SC integrity and cohesion as well as for an intact antimicrobial and 
epidermal permeability barrier [3]. The composition and homeostasis of the skin is crucial for its barrier 
function and is therefore essential for the penetration ability of APIs [55]. 
 
SC 
The SC and its heterogeneity ensures the barrier function and acts as the main and primary defensive 
line for exogenous substances [56]. Therefore, the composition of the SC lipid envelope contributes to 
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the maintenance of the skin barrier function [12]. The lamellar structure of the intercorneocyte space 
leads with its lipid bilayer and complex non-polar lipids to an intact barrier function. The most 
abundant SC lipids are ceramides, which are important for water transport and barrier function, which 
leads to effective epidermal barrier function [57-59]. The SC provides a reservoir function, which is 
directly linked with its barrier ability over time. By increasing the thickness of the SC, the reservoir 
function decreases with increasing barrier function [60]. The reservoir capacity of the SC is limited and 
its saturation is dependent on donor, application site, substance, and formulation [21]. Also, its 
interaction and affinity to certain drugs provides an accumulation of the active ingredient in the SC, 
which leads to local action of the drug [21]. It is known that lipophilic drugs like corticosteroids, with a 
characteristic log P of 1-4, have good skin permeability properties especially across the lipophilic SC 
environment [28, 61]. Therefore, the SC polarity or lipophilicity is assumed to be 0.8 [51]. Depending 
on the species, the thickness of the SC and lipid composition varies, with pigs having the thickest and 
mice the thinnest SC among mammalians. The penetration abilities of APIs correlate to a certain extent 
to the SC thickness, since several structural differences influence this complicated process [21].  
 
Viable epidermis 
The target-site penetration inside the viable epidermis depends on the permeability of the drug across 
the SC and the impermeability into the dermis. After overcoming the first line of defense, the SC, or 
the aqueous epidermis, might be the tissue of interest for target-site penetration or needs to be passed 
through to reach the dermis. Lipophilic compounds that overcome the SC barrier, often demonstrate 
reduced penetration rates if the more hydrophilic epidermis is reached [38]. Between the viable 
epidermis and the dermis is the basement membrane located, which builds with the presence of tight 
junctions a significant permeability barrier that affects the transport of drugs. The barrier function of 
the basement membrane is mainly impermeable for negatively charged macromolecules and large 
substances. On the other hand, tight junctions form a permeability barrier for small, intermediate, and 
large size molecules as well as ions [55, 63]. The stratum granulosum provides with the junction 
proteins claudin, occluding, and tricellulin a physical barrier for substances [7]. In addition, the lamellar 
body organelles are considered to be an essential part of the stratum granulosum barrier function with 
a closely linked antimicrobial function of antimicrobial peptides like cathelicidine [3]. The lamellar 
bodies are important for the formation, maintenance, and repair of epidermal barrier function. In 
addition to their contribution to the epidermal permeability barrier they influence the defensive 
function exerted by the SC. The drug binding capacity, sequestration, metabolism, and active transport 
in the layers of the viable epidermis harms the availability of active ingredients inside the dermis [64]. 
Owing to its role as the first line of immune defense, there is a need for direct delivery of the drugs to 
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certain skin layers. The lower epidermis contains melanocytes and Langerhans cells and is therefore a 
local target-site and specific penetration to this area by avoiding transport through the dermis is 
desirable [27]. [3, 7] 
 
Dermis 
The metabolic activity and capacity of the epidermis exceeds that of the dermis [13]. Divided into the 
upper papillary and the lower reticular layer, the upper dermis exhibits thinner and looser packing of 
collagen fibers. The papillary part interdigitates with the basal layer and builds a dermo-epidermal 
junction [12]. After the API passes the aqueous epidermis and enters the aqueous dermis, it penetrates 
the tissue and moves through the layers via passive diffusion. In the dermis, active ingredients may 
enter the blood stream or the lymphatic circulation, which leads to systemic exposure. The 
microvasculature and lymphatic system is mainly present at the top 1-2 mm of the skin, due to which 
drugs are cleared from their target-site via systemic transport [65, 66]. The transfollicle route is 
important to accumulate drugs in the dermis, which enables drug targeting with a sustained effect 
[67]. Regional accumulation inside the dermis is indispensable for the prevention and treatment of 
local skin diseases [7]. 
 
Appendages 
The surface area containing hair follicles is highly dependent on the body region and extends the skin 
area as well as the penetration area from a maximum of 13.7 % at the forehead to a minimum of 1 % 
at the forearm [68]. This variance is caused due to different volumes and the different amount of hair 
follicles at different body sites. The hair shaft increases the epithelial surface area and confers a 
reservoir function as well as an interface for the interaction of drugs. Physico-chemical drug properties 
(lipophilicity and molecular weight), vehicle, and formulation types are highly important for its 
penetration ability and also influence the distribution of the drug [69]. The lower part of the 
infundibulum acts as a main entry point for drugs, since the barrier function of the hair follicle is 
interrupted [7]. In this upper appendage shaft, there is a dense capillary network, which facilitates 
drugs to enter the systemic circulation more effectively. These transappendageal pathways have 
gained increasing interest and have been for a long time overlooked as an efficient penetration route. 
Increasing evidence has revealed the importance of hair follicle penetration as a fast entry route into 
the skin and is now being discussed as a shunt route [7]. The transfollicular pathway allows for 
enhanced penetration into deeper sites, prolonged residence duration, and site-specific targeting [70]. 
In contrast, other appendage pathways such as the sebaceous and sweat glands have been poorly 
investigated, due to difficulties with precise local detectability [71]. Exclusive penetration via the hair 
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follicle can be studied and blocked by using nail varnish; Klein et al. demonstrated that nail vanish 
provides secure follicular closure by not increasing the penetration of the active ingredient [72, 73]. 
There are active follicles inside the skin, which secret sebum and are local points for hair growth and 
passive follicles, but their activity remains unknown this far. Only active follicles are relevant for topical 
skin penetration [74]. Physiological factors such as hair growth cycle and regional variation affect 
follicular penetration [39, 75]. The sebaceous glands create a neutral and non-polar lipid environment, 
which offers a potential penetration pathway for lipophilic molecules [39]. Lipophilic formulations and 
the physico-chemical character of the active ingredient play an essential role in follicular trafficking, 
and some drugs are known to exclusively penetrate via this route [76]. The physico-chemical properties 
of hydrophilic molecules (caffeine), electrolytes, and larger molecules favors transfollicular 
penetration. 
 
Lateral diffusion 
Recent research states that lateral diffusion needs to be considered in penetration studies and more 
passive API movement takes place than previously thought. APIs are spreading on top and within the 
upper layers of the SC. Predominantly lipophilic molecules diffuse laterally within the SC [77]. This 
movement is restricted by a topically applied fence around the application site, which leads to 
decreased spreading of the active ingredient. A recent study showed that lateral penetration of APIs 
within the viable epidermis and dermis has an impact on the overall penetration within the skin [78]. 
To better understand this concept, penetration models need to be updated to be able to study lateral 
penetration. 
 Penetration models 
The penetration ability and percutaneous absorption of the skin varies largely with age, sex, ethnicity, 
size, weight, and body region [79]. Penetration models are important to investigate the efficacy and 
quality of topically applied active substances in a formulation [2]. To study the dermal and transdermal 
delivery of drugs through the skin in silico, in vitro, ex vivo and in vivo experimental studies are 
accomplished [38].  
In silico skin models are used to predict the permeability of active compounds. This approach is based 
on theoretical-mathematical simulations derived from structure-based permeation models. 
Experimentally validated data correlate with the concentration-depth profiling of SC penetration 
simulations. However, the use of molecular dynamic simulations is limited and provides a first simple 
assumption of penetration abilities. [80] 
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In vitro skin models are designed for transdermal drug delivery testing with the utilization of artificial 
membranes or reconstructed human skin. Artificial membranes are synthetic skin alternatives 
containing silicone, multiple layer polyether sulfone, or synthesized copolymer membranes. The Strat-
M® membrane is a non-animal based, synthetic artificial membrane, which is built up in multiple layers 
of polyester sulfone, coated with lipids, specially designed to mimic the skin structure. Artificial 
membranes have the potential to be screening models, by providing trends and correlations for 
penetration enhancement ability. They provide a beneficial low intermembrane variation, which leads 
to better trend estimation of API and formulation penetration abilities. [81] 
Apart from skin-mimicking artificial membranes, some in vitro models are based on reconstructed skin, 
using human epidermis and dermis cells. There are multiple models such as Graftskin™, SkinEthic™, 
HRE, and Episkin that have been established for penetration testing [82, 83]. Those skin models are 
limited as surrogate models due to their high penetration ability [84, 85]. Both in vitro skin model 
systems have a lower barrier function, which leads to higher penetration rates [86]. Nevertheless, 
artificial membrane in vitro assays are a valuable tool to predict penetration. 
In vivo human penetration studies represent the most accurate method to predict efficient penetration 
abilities with in vivo relevance [87]. There are multiple options on in vivo human penetration studies. 
For example, a biopsy removal as an indirect in vivo method provides valid information about a 
substance’s depth profile inside the skin. After topical application, the SC is fully removed via tape 
stripping [88] or cyanoacrylate stripping [89], or the full epidermis is removed via heat-separation [90] 
for depth profiling. This invasive method is limited due to ethical reasons. In vivo confocal laser 
scanning microscopy provides valuable information about three-dimensional skin structure and the 
localization of an active ingredient inside the skin [91]. This technique is limited to fluorescence 
substances which are semi-quantitatively coupled to the active ingredient. Another technique for 
depth profiling is in vivo Raman imaging [92]. APIs are localized and significant skin structures are 
detected via semi-quantitative analyses. The minimally invasive microdialysis in vivo setup is used to 
identify the penetration of active ingredients into the skin and does not show any swelling or onset of 
inflammation due to insertion of the membrane [93, 94]. Due to ethical reasons and limited access to 
in vivo human skin, penetration experiments with different alternative models have been proposed. 
As an alternative skin model, the skin from pigs, rats, hairless mice, rabbits and snakes has been used 
[95]. In vivo studies have established a penetration rate trend for percutaneous substances: rabbit > 
rat > porcine skin > human [96]. To compare the absorption rate of different skin species, the 
penetration rate needs to be considered. Due to ethical reasons and the derived animal ban 
restrictions in the European Union for cosmetic ingredients and products, animal testing has been 
prohibited since 2013 [97]. The use of animal waste products from food production is a permissible 
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alternative method. An alternative to in vivo human studies is the use of in vitro and ex vivo skin for 
percutaneous penetration testing, which is accepted by the Scientific Committee on Consumer Safety 
(SCCS) [98].  
Ex vivo human skin, which is obtained from plastic surgery, is regarded as most representative to in 
vivo human skin. Excised human skin is limited and difficult to access [21, 99]. The OECD guidelines 
recommends porcine ear skin as a suitable model for percutaneous penetration studies [44]. The 
composition of the SC and epidermis as well as the lipids and hair follicle density inside the skin is 
among other factors important to compare penetration rates. The follicle density is dependent on the 
species and most animals exhibit a higher density than humans [68]. Considering human mimicking 
models, porcine ear skin has similar dimensions of hair follicles but with a larger diameter [100]. In 
addition to the follicle density, the morphology and penetration abilities of porcine ear skin are 
comparable to those established in vivo human studies for topically applied substances [101, 102]. The 
SC shows a uniform arrangement of corneocytes with a similar number of cell layers [21]. Compared 
to the whole porcine body with a thickness of 17-28 µm for the SC and 60-85 µm for the viable 
epidermis, the SC of the porcine ear is with about 19 µm rather thin [103, 104] and with about 24-38 % 
of total epidermis thickness comparable to the 16.8 µm SC of humans [95]. In general, the absolute 
thickness of the epidermis and dermis of the porcine ear skin corresponds to that of the human skin 
(Table 1) [103]. 
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Table 1: Comparison of human and porcine skin layers with average thickness [105]. 
 
For penetration testing, ex vivo human and porcine skin models are the specimens of choice [107]. 
Porcine ear skin is reported as more suitable than excised human ex vivo skin due to the presence of 
cartilage inside the ear, which leads to less contraction and a more stable tissue [108]. For ex vivo 
percutaneous penetration studies, separation of the skin into the SC, epidermis, and dermis, post 
experiment provides a suitable penetration profile of the concentration of the compound per layer. 
The passive diffusion of APIs is experimentally studied using ex vivo and in vitro percutaneous 
penetration diffusion cell models. Two types are commonly used, the static or flow-through diffusion 
cell [38]. The flow-through penetration system provides continuous replacement of the receptor fluid 
(RF) in contrast to the static diffusion cell system. Using surrogate skin systems to investigate 
penetration, the Franz Diffusion Cell (FDC) has been applied since 1975, and is the most commonly 
used static diffusion cell setup [109]. This method with its simple design is used for in vitro and ex vivo 
penetration studies. The cell system consists of a receptor chamber filled with a RF in which the 
compound is released after penetrating through the skin. The RF is constantly stirred and the receptor 
chamber is temperature controlled at 32°C for cosmetic studies and 37°C for dermatological or 
pharmaceutical penetration studies. For in vitro penetration studies artificial membranes, and for ex 
vivo penetration studies, skin is mounted on the receptor chamber. When using skin, either full-
thickness or split-skin is used as the surrogate system. Most percutaneous penetration studies use 200-
500 µm dermatomed split-skin, which exhibits only the upper part of the dermis, making the difference 
in the dermis thickness less important for interpretation of penetration ability [110]. The donor 
chamber is placed on top of the skin to ensure correct topical application of either an infinite dose 
(>100µL/cm²) or finite dose (10µL/cm²) [105, 111]. This setup allows the evaluation of concentration 
kinetics as well as determination of the absolute amount of an active ingredient within different skin 
layers. Cumulative sampling allows for analysis of the kinetic progression of penetration, and by 
individual sampling, the total amount of penetrated API is determined. Penetration kinetics allow to 
predict the bioavailability, which is important to ensure the efficacy of the compound exposed to the 
living cell entity targeted by the API. In order to determine the concentration in the respective skin 
depth, the skin is separated into different layers and the active amount is analyzed. The major 
 SC Epidermis Dermis Reference 
Human 16.8 μm  70 μm  1.20 mm Qvist et al. (2000) [106] 
Bronaugh et al. (1982) [95] 
Pig 19 μm  
(17-28) 
72 μm  
(60-85) 
1.86 mm  
(1.44-2.25) 
Jacobi et al. (2007) [104] 
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disadvantage of the FDC is the invasive preparation of the skin samples, which possibly results in 
trauma and thus does not adequately mimic healthy skin conditions [112]. 
 
Figure 4: Schematic illustration of a the FDC. Figure modified by M. Lubda. [113] 
 
Flow-through diffusion cells for skin research have gained popularity within the field of neuroscience. 
The microdialysis (MD) system, which is the most used flow-through system, is used in dermatology 
research. The continuously replaced RF mimics the in vivo circulation of blood inside the skin. A 
formulation containing the active ingredient is topically applied on the skin, and then penetrates and 
diffuses inside the different tissue layers. The application site is defined with a fence to ensure a 
spreading within the desired area. A semi-permeable membrane, which is placed underneath the skin 
is flushed with a perfusate, mimicking a small blood vessel in the skin [114]. The active ingredient, 
which penetrates the skin, is collected inside the membrane and flushed by the perfusate, enabling 
sampling. The flow rate is an important factor limiting the penetration and affecting the relative 
recovery, which is an indicator of the performance of the MD system. The higher the flow rate, the 
higher the recovery rate, but the less active ingredient is found in the perfusate; a flow rate between 
1 and 5 µL/min is commonly used to ensure a steady state diffusion into the membrane [115]. The MD 
setup allows to detect small molecules, like APIs as well as endogenous molecules such as cytokines 
[116, 117]. The membranes are defined by their molecular weight cut-off, which is an important factor. 
Therefore, the molecular weight cut-off should be 10-times larger than those of the collected 
molecules, to achieve a high recovery of the active ingredient [116, 117]. While performing the MD 
experiments, the localization of the membrane inside the skin is important. The membrane is placed 
in a defined depth, which enables the determination of the penetration depth for each respective 
substance. In recent research, the depth has been controlled via ultrasound after the experiment has 
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been carried out [118]. Ideally, depth validation is performed prior to the experiment. Using 
ultrasound, the skin is treated with gel to receive a detailed image, but the gel has an impact on the 
penetration. A not yet described alternative method, is the depth analysis determined via computed 
tomography. This non-invasive method allows to determine the depth of the membrane before the 
experiment. MD has several benefits, including its minimally invasive experimental setup and 
continuous monitoring of the pharmacokinetic and pharmacodynamic studies of in vivo, ex vivo, and 
in vitro experimental setups [119]. 
 
 
Figure 5: Schematic experimental setup of the microdialysis. Figure modified by M. Lubda. [120] 
 
The perfusate which is flushed through the MD membrane and the RF of the FDC needs to dissolve the 
active ingredient without degrading it. This fluid is a physiological solution that mimics the blood or 
the skin environment [121]. In most percutaneous penetration studies, phosphate buffered saline 
(PBS) or Ringer Solution is used for hydrophilic molecules as the physiological fluid. For molecules with 
a lipophilic character, the perfusate needs to be optimized to ensure the solubility of the active 
ingredient. The recovery of APIs is increased for lipophilic molecules, by adding solubility enhancers 
like albumin, cyclodextrines, or the surfactant Brij [105, 122, 123].  
The barrier function of skin is commonly linked to transepidermal water loss (TEWL), which describes 
the loss of water in gram per surface area over time and provides information about the integrity of 
the skin. To ensure the integrity of the skin, TEWL, infrared spectroscopy, and impedance spectroscopy 
are used to distinguish the barrier function of the skin [124-126]. The determination of the TEWL occurs 
prior to the penetration experiment and is the commonly used method to analyze barrier-disruption 
of the skin [3]. The post-experimental quantification of the active concentration is performed using 
HPLC. 
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 Influences on the penetration of the API 
The kinetics of percutaneous penetration studies and the ability of an API to reach its target-site is 
influenced by multiple factors. The penetration ability is dependent on the physico-chemical 
properties of the API itself. Besides the characteristics of the API, the formulation or vehicle 
components, which surround the active ingredient, influences the penetration ability. External factors 
and application of the API containing formulation influences the penetration depth and rate. 
 
API 
The passive diffusion of most APIs follows Fick´s law, and therefore, the physico-chemical properties 
of APIs are important and influence the permeability coefficient, which modulates its penetration 
ability [38]. In particular, the molecular size analog to Stokes surface, expressed as molecular volume 
and molecular weight and the lipophilicity, which is expressed with the log P value, influence the 
penetration [127]. 
As a general rule, molecules with a molecular weight smaller than 500 Da penetrate the skin passively 
[62]. Molecules with a higher molecular weight have the potential to passively or actively penetrate 
the skin, but to increase the penetration rate, an electrical or mechanical enhancement is 
recommended [128]. With increasing molecular weight, the penetration rate decreases, defined by 
the diffusion coefficient. The lipophilicity is defined by the octanol-water partition coefficient (Ko/w), 
describing the concentrations of the dissolved molecule in the organic octanol and aqueous water 
phase [129]. This coefficient is expressed as log P and positive values indicate lipophilicity and negative 
values hydrophilicity. Therefore, a log P of 1-3 permeates skin most readily [12] and APIs need a 
lipophilic characteristic to enter the SC and a hydrophilic characteristic to pass through the viable 
epidermis [49]. The log P describes the solubility characteristics of an API. To ensure penetration, the 
API needs to be dissolved in the formulation. The solubility of an API is linked to its melting point; as a 
rule of thumb, active ingredients with a melting point of less than 200°C are said to penetrate the skin 
[130]. A high solubility leads to a high concentration gradient, which increases the diffusion force 
across the skin. The penetration rate of an active ingredient is optimized by a low molecular weight, a 
low melting point, and moderate lipophilicity. Besides this, the main characteristics of an API such as 
the vapor pressure, the ionization with its pH dependency, hydrogen bonding activity, and the affinity 
for protein binding affects the percutaneous penetration [12, 38]. 
To study the main effects of the physico-chemical influences on skin penetration of APIs, the molecular 
size and lipophilicity of compounds are tested. Caffeine is recommended by the OECD guidelines as a 
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model compound for in vivo, ex vivo, and in vitro penetration studies [44]. The methyl xanthine alkaloid 
caffeine is hydrophilic in nature, moderately soluble in water and well known for its penetration 
behaviour [131]. Furthermore, the physico-chemical properties of the active ingredient LIP1 are of 
interest but its penetration abilities are unknown. LIP1 is a lipophilic molecule with a low molecular 
weight and low solubility in water. Caffeine and LIP1 have a similar molecular weight with a difference 
in the lipophilic characteristics, which makes them ideal for comparative penetration studies (Table 2).  
The penetration is influenced by the physico-chemical characteristics of the molecule itself as well as 
the vehicle and external factors. 
Table 2: Physico-chemical properties of caffeine and LIP1. [131] 
 Caffeine LIP1 
Chemical structure 
 
 
Molecular weight [g/mol] 194.19 194.19 
Log P  -0.1 (exp.) 0.6 (exp.) 
Melting point [°C] 236 (exp.) 179 (exp.) 
Solubility in H2O [25°C] 21.6 mg/mL (exp.) 0.75 mg/mL (exp.) 
Solubility in PGOA [25°C] 7.2 mg/mL (exp.) 52.0 mg/mL (exp.) 
CAS number 58-08-2 65609-28-1 
 
Formulation 
To ensure target-site specific penetration of APIs, the formulation, which is described as the vehicle of 
the API, is important. The formulation allows to optimize the delivery of active ingredients into the skin 
and needs to be designed individually for each API [51]. Most APIs are formulated into a standard 
formulation, almost exclusively based on their physico-chemical properties and solubility 
characteristics. Due to complex formulation processes, formulation development is initiated after the 
efficacy testing. Many different compounds, such small hydrophilic and lipophilic molecules, 
surfactants, lipids, and solvents are part of a formulation. They are divided into different classes and 
most of them have a penetration enhancing effect and improve the penetration of the API. Penetration 
enhancers increase the penetration rate of APIs in different ways but should ideally not irreversibly 
change the skin morphology. Therefore, the following hydrophilic and lipophilic penetration 
enhancements are described [132]. Hydrophilic penetration enhancers interact with the hydrophilic 
groups of the phospholipid bilayer, which leads to reorganization of the lipid chain, due to unbound 
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water. Lipophilic penetration enhancers loosen the parallel structured lipid chains. Some solvents 
increase the solubility of the API in the aqueous phase or oily phase, which leads to a higher 
concentration gradient. [8, 51, 133] 
 
 
Figure 6: Lipid bilayer of the SC and the enhancing effect on the penetration of hydrophilic and lipophilic penetration 
enhancers. [132] 
 
Penetration Enhancers 
 
Emollients: 
Most emollients are added to a formulation as a refatting agent, they are substances that soften the 
skin and slow down the evaporation. Beeswax, almond oil, paraffin, and glycerol are commonly used 
emollients. They have a broad penetration enhancing effect, and polar emollients are particularly 
known to promote API penetration. [134] 
Surfactants: 
Surfactants are detergents present in multiple skin products. They alter the TEWL and the transition 
temperature of SC lipids and disturb the SC diffraction patterns [135]. Surfactants such as sodium 
dodecyl sulfate are known for their penetration enhancing function, which elicits an irreversible effect. 
They affect both the intra- and intercellular pathway and lead to SC swelling [136]. 
 
Azone®: 
Laurocapram or Azone® is a hybrid of pyrrolidone and decylmethylsulfoxide, which are potent 
penetration enhancers. This lipophilic molecule is especially designed to achieve a skin penetration 
enhancing effect. Azones® interrupt the lipid packing by partitioning into the lipid bilayer and increasing 
the skin permeability for hydrophilic and hydrophobic drugs [137]. Combined with propylene glycol, 
Azones® are known to enhance the penetration flux of actives across the skin [138]. 
Humectants: 
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Those osmolytes are small, polar compounds like urea and glycerol, are naturally present in the SC and 
are known to moisturize the skin [139, 140]. They cause increased mobility in the ceramide 
headgroups, which leads to a penetration enhancing effect, paired with hydrophilicity [141]. 
Humectants partition into the aqueous regions between the lipid lamellas and therefore loosen the 
lipid packing, as well as inside the corneocyte [8]. 
Glycols: 
Glycols are commonly part of the aqueous phase of a formulation and are known to have a penetration 
enhancing function [142]. In addition to their penetration enhancing effect on the skin, they increase 
the exposure of the API to the solvent, thereby increasing its solubility. Propylene glycol (PG), butylene 
glycol, ethoxydiglycol, and glycerol are commonly used glycols and are present in different 
formulations. PG as a co-solvent is the most commonly used glycol and is combined with other 
penetration enhancers like fatty acids for percutaneous penetration study formulations [143]. PG 
increases the API solubility and its penetration enhancing function is based on interactions with the 
polar headgroups or the hydrocarbon chains of the SC bilayers [143]. 
Fatty acids: 
There are two different types of fatty acids: saturated and unsaturated fatty acids. They are the main 
components of the SC lipids with a long acyl chain and are known to increase the penetration into the 
skin [144]. The unsaturated form of the acyl chain promotes penetration across the skin more than the 
saturated form when comparing chains of the same length. Fatty acids affect the mobility of the SC 
lipids, especially of cholesterol and ceramide headgroups with high water content. They are used to 
increase the penetration rate of hydrophilic and hydrophobic APIs [8]. Fatty acids such as oleic acid 
(OA) are known for their penetration enhancing effect; they lower the barrier function while 
interacting with the polar and non-polar groups of the SC lipids [143]. 
 
External factors 
External factors, such as occlusion, temperature, mechanical manipulations, and physical forces have 
an impact on the API penetration into the skin. 
 
Occlusion: 
Occlusion of the skin is achieved by covering the skin with a vapor-impermeable membrane or by 
infinite dosage [87]. This leads to differences in the hydration, barrier permeability, differences in 
epidermal lipid synthesis and differences in molecular and cellular processes [3]. An infinite amount of 
formulation leads to a steep concentration gradient and hydration of the SC due to an occlusive effect: 
both increase the penetration of active ingredients. Engorged corneocytes, increased temperature, 
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and increased hydrostatic pressure from large application volumes causes occlusion which in turn 
increases the ability of an API to penetrate the skin [145]. Due to a mobile disorder and hydrated 
conditions the lipids and protein components of the SC change their fluidity [146]. 
 
Temperature:  
Increasing skin temperature due to either external or internal influence increases the permeability of 
skin due to occlusion [147]. This can be due to vasodilation, which leads to higher blood circulation 
and higher evacuation of the active ingredient. At room temperature, the main parts of the SC lipids 
and proteins are solid; with an increasing temperature they become more fluid, which leads to 
increased permeability [8]. Increasing the temperature from 25°C to 40°C changes the skin 
permeability and significantly increases the penetration flux by more than 3-fold [148].  
 
Physical forces: 
Electrical voltage achieved via iontophoresis or electroporation, ultrasound by sonophoresis, and 
microneedles are used to overcome the barrier function and increase skin penetration [149]. 
Microneedles, with their needle-like microstructures, increase site-specific drug delivery by controlling 
the length of the needles without invasive stress [150]. These techniques are designed to enhance skin 
penetration and disrupt the skin without long-term compromise of its barrier function. 
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5 Materials & Methods 
 Materials 
5.1.1 Reagents 
Caffeine, LIP1, Milli-Q® (H2O), acetonitrile, neutral buffered 4 % Formaldehyde solution, paraffin 
pastilles, Neo-Clear® and eosin Y-solution 0.5 % alcoholic were purchased from Merck KGaA 
(Darmstadt, Germany). Propylene glycol (PG), Oleic acid (OA), and Hematoxylin Meyer solution were 
purchased from Sigma Aldrich by Merck KGaA (St. Louis, USA). PBS with magnesium and calcium 
(PBS++) was purchased from Biowest (Nuaillé, France). Window color was obtained from Marabu 
GmbH & Co. KG (Tamm, Germany) and cyanoacrylate super glue by UHU GmbH & Co. KG (Bühl, 
Germany). 
 
5.1.2 Formulations 
Caffeine-H2O solution 
Caf-H2O and Caf-PBS were prepared with 2 % or 0.7 % caffeine (w/w), respectively. 
Caffeine-PG and Caffeine-PGOA solution 
Caf-PG and Caf-PGOA with 5 % OA (w/w) were prepared with a concentration of 0.7 %. 
LIP1-PG and LIP1-PGOA solution 
LIP1-PG and LIP1-PGOA with 5 % OA (w/w) were prepared with a concentration of 0.7 %. 
 
5.1.3 Materials 
Linear EP Low Flux Probes were purchased from EP Medical (Copenhagen, Denmark). Guide canula 
(G18, 0.60 mm × 25 mm, 100 Sterican®), Omnifix-F 3mL syringes and Perifix® catheter connectors (latex 
free, 19G, 1.05 mm) were purchased from B. Braun (Melsungen, Germany). Univentor 864 Syringe 
pump by Univentor (Zejtun, Malta). Makro disposable cuvette were purchased from BRAND GmbH + 
Co. KG (Wertheim, Germany). Eppendorf and PCR tube were purchased from Eppendorf (Hamburg, 
Germany). Tesafilm® crystal clear 4129 were purchased from Beiersdorf (Hamburg, Germany). Millex® 
syringe filter 0.22 µm PES and Strat-M® membrane were purchased from Merck KGaA (Darmstadt, 
Germany). Cotton was purchased ebelin dm-drogerie markt GmbH + Co. KG (Karlsruhe, Germany). 
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 Methods 
5.2.1 Artificial membranes 
The Strat-M® membrane is a synthetic, non-animal-based model, which comprises multiple layers of 
polyestersulfone and is coated with lipids that mimic the skin structure for penetration testing. 
 
Figure 7: Multilayered structure of the Strat-M® membrane. Scanning electron microscopic image of a cross-section of Strat-
M®. First (i), second (ii), and third layer (iii). [81, 151] 
 
5.2.2 Porcine skin 
Porcine ear skin was used as an ex vivo model for human skin as described in the OECD and SCCS 
guidelines. Pig ears (German domestic pigs, 6-month-old) obtained from a local slaughterhouse 
(Brensbach, Germany), freshly slaughtered, were washed and cleaned with rinsing water and then 
dried using soft tissue and stored at +4°C for a maximum of 72 h. The skin from the back of the ear was 
dermatomed with an electrical dermatome from Humeca BV (Borne, Netherlands) at a thickness of 
300, 500, 700, and 1000 μm, respectively. Six skin punches with a diameter of 26 mm were obtained 
from each ear.  
 
5.2.3 Human skin 
The human skin was obtained from Genoskin (Toulouse, France), stored at -20°C until a maximum of 
half a year. Due to company safety reasons, fresh ex vivo skin could not be used for penetration testing. 
The skin obtained from the abdomen of female donors was dermatomed with an electrical dermatome 
at a thickness of 500 μm. Six skin punches with a diameter of 26 mm were obtained from each donor. 
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5.2.4 Skin thickness 
Micrometer screw gauge measurement 
To determine the thickness of the dermatomed skin discs for use in the experiments, the thickness was 
monitored by making four thickness measurements at the outer edge of each disc using an electrical 
digital micrometer (0-25 mm/0.001 mm) from Vogel Germany GmbH & Co.KG (Kevelaer, Germany).  
 
Figure 8: Schematic diagram of dermatomed skin representing each skin disc (Disc) used for the penetration testing and the 
9 mm application site (Middle) with four outer edge measurement sites (Measurement Site) to determine the mean thickness 
of the disc. 
 
To enable this, the skin samples were placed between two cover slips and the thickness was measured 
using the micrometer considering the first point of physical contact to avoid compression of the tissue. 
 
Microscopic measurement 
To determine the thickness of the dermatomed skin with a microscope, small samples next to the outer 
edge of each stamped disc were obtained and cut into 10-µm thick vertical tissue sectionings using a 
Leica CM1520 cryo-microtome from Leica Biosystems (Nussloch, Germany) at -30° C. The skin thickness 
was measured using a bright field microscope (Carl Zeiss, Munich, Germany) and the pictures were 
analyzed via the ZEN Blue Edition 2.1. software by (Carl Zeiss, Munich, Germany). 
 
5.2.5 TEWL 
The TEWL measurement was performed with an open chamber TEWL device CORTEX system from 
BONDERM GmbH (Biberach, Germany) and each membrane and skin disc were measured five times. 
 
5.2.6 Franz Diffusion Cell (FDC) 
Six skin discs/artificial membranes were placed onto the FDC (9 mm diameter, diffusion area 
0.636 cm²) from Logan Instruments Corp. (Somerset, USA). The skin was placed dermal side down and 
the artificial membrane shiny side up onto the receptor chamber. The receptor chamber filled with the 
physiological buffer PBS was temperature controlled at 32 ± 1°C and constantly stirred. Before placing 
the donor chambers onto the discs, the TEWL was measured monitoring room temperature and 
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humidity. After an equilibration of 30 min, the formulation was topically applied with 10 µL/cm² (finite) 
or 786 µL/cm² (infinite). At defined time points, samples were obtained using a Millex® syringe filter 
unit. 
 
5.2.7 Skin separation 
The SC, viable epidermis (E), and dermis (D), were separated for individual skin layer analysis. After 
each FDC experiment, the donor chambers were washed with 2 mL PBS. The formulation residues on 
the skin were removed with cotton wipes, applying constant pressure with a roller from 
Speedball/Brayer (Statesville, USA) and collected in 2 mL tubes; this was termed skin wash (SW). 
SC removal: 
The SC was removed by five cyanoacrylate superglue tape stripes, which were homogeneously applied 
with a constant pressure by a roller. The application site was marked on the skin surface. After 
incubating for 2 min, the tape strips were removed against the grain of hair growth. The demarcated 
area was punched out, with a diameter of 9 mm and collected in a 2 mL tube; all five stripes were 
determined as SC. The remaining tapes were collected in a 5 mL tube for lateral diffusion analysis (SC-
lat).  
E/D removal: 
To separate the E and D, the application site was punched out of the skin discs. These were placed D 
side down on a 60°C heating plate from IKA® (Staufen, Germany) for 90 s and the E was carefully peeled 
off with forceps. The E and D were weighed and collected in 2 mL tubes each. The remaining skin was 
collected in a 2 mL tube (Lateral). 
The donor chamber wash (DC), skin wash (SW), SC, viable epidermis (E), dermis (D), receptor fluid (RF), 
lateral diffusion in SC (SC-lat) and skin discs (Lateral) were obtained, respectively. Adding 1 mL PBS and 
a 5 mm metal ball, the tubes with the skin tissue were shaken in a TisseLyser II from Qiagen (Hilden, 
Germany) for 10 min at 30 Hz two times and the balls were removed afterwards. Adding to all tubes 
2 mL, except for the SC-lat 5 mL, and for the Lateral 1.5 mL, PBS in total, respectively. The samples 
were incubated for 20 h on a tube roller from Stuart equipment (Staffordshire, UK) at 60 rpm and 
filtered subsequently.  
 
5.2.8 Hematoxylin-eosin (HE) staining 
Preparation of the Paraffin Samples 
For the skin separation morphology images, the skin tissue was removed from the cartilage. The skin 
was fixed in formalin by incubation in buffered formalin (4 %) for 48 h at RT. For paraffin infiltration, 
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the skin was transferred to ascending concentrations of ethanol for 1 h each at RT in the sequence: 
70 %, 2x 95 %, 2x 100 %. They were transferred into a xylene solution incubating twice for 1 h at RT. 
The tissue was incubated in paraffin wax at 56°C over night and after this was repeated 2x for 1 h and 
the tissue was then embedded in paraffin blocks. 
 
Tissue Sectioning and Staining 
The paraffinized skin was cut into 4 µm vertical sections using a CUT6062 microtome from SLEE medical 
GmbH (Mainz, Germany). The sample HE staining was performed according to the following protocol. 
 
Table 3: HE staining protocol for porcine tissue. 
Chemicals Incubation Time [min] 
NeoClear 5 
NeoClear 5 
100 % EtOH 2 
96 % EtOH 2 
70 % EtOH 2 
Aqua dest. 2 
Aqua dest. 2 
Haematoxylin 3 
H2O 1 
H2O 3 
70 % EtOH 2 
Eosin 0.5 
96 % EtOH 1 
96 % EtOH 2 
100 % EtOH 2 
NeoClear 5 
NeoClear 5 
The images were visualized using a brightfield microscope (Carl Zeiss, Munich, Germany) and the 
pictures were analyzed via the ZEN Blue Edition 2.1. software provided by Carl Zeiss (Munich, 
Germany). 
 
A Untreated B SC removal 
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C E removal 
 
Figure 9: HE stained porcine full-thickness skin after skin layer. A: untreated skin. B: Skin after stratum corneum (SC) removal 
by cyanoacrylate tape stripping. C: Skin after heat-separation of Epidermis (E) and dermis (D). The SC, E, and D are marked 
with arrows. 4 µm sections. Scale bar = 50 µm. 
 
 Microdialysis (MD) 
5.3.1 Implantation of the membrane in the skin 
The porcine ear was pinned dermal side down to a solid surface and the hair was cut manually. The 
cannulas used as insertion guides were implanted and a 1 cm² application site was defined with 
window color fence as the site of topical administration with 1 cm between each application site. The 
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membranes were inserted in the skin with a defined depth and a defined length of the membrane 
accessible to dialysis (insertion length). The membranes were continuously perfused with PBS and an 
experimental flow rate of 3 µL/min throughout the experiment. The membranes were primed with a 
flow rate of 25 µL/min for 20 min and for 30 min with the experimental flow rate outside the skin. 
After insertion into the cannula the membrane was primed with the experimental flow rate for 10 min, 
the cannula was retracted and primed implanted in the skin for 30 min. The membrane was implanted 
in the middle of the application site and for lateral penetration studies two membranes were placed 
additionally at the edge of the application site. The skin was allowed to equilibrate before topical 
administration of 10 µL/cm² formulation. After the application the perfusate was collected in PCR 
tubes at the probe outlet and sampled every 30 min for 8 h under tracked relative humidity and room 
temperature conditions. All experiments were performed by the same operator in the laboratory. 
 
Figure 10: Schematic experimental setup with application site and membrane. A: Experimental setup with membrane in the 
middle (1) of the application site. B: Experimental lateral setup with membrane in the middle (1) and two membranes (2 & 3) 
at the edge of the application site. 
 
5.3.2 MD membrane: 
The 2 kDa Cellulose cuprammonium (Cuprophan) membrane ( = 215 µm) with micropores were 
purchased from EP Medical (Copenhagen, Denmark) were used in MD. 
5.3.2.1 Membrane surface structure visualization 
To visualize the MD membrane scanning electron microscope (SEM) pictures were taken with a Supr35 
Zeiss device by Carl Zeiss (Munich, Germany). The membrane Probes where sputtered with a platinum 
cover of 10 nm with the Sputtercoater Q150T ES from Quorum Technologies Ltd (Laughton, UK) and 
the measurement were done under vacuum control and with 30 mA measurements. 
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Figure 11: SEM images from the 2 kDa MD membrane. 
 
5.3.3 Membrane depth measurement 
The depth in the MD experiments in which the membrane was inserted inside the skin was determined 
via computer tomography (CT), ultrasound, and microscopically.  
 
5.3.3.1 Measurement via CT 
The depth of the linear probe was determined with the SkyScan 1176 from Bruker Corporation 
(Billerica, USA), a stand-alone high performance in vivo/ex vivo micro-computer tomographe. The lead 
wire inside the microdialysis membranes is detected with a precision of 9 µm. The Bruker DataViewer™ 
by Bruker Corporation (Billerica, USA) was used to perform the analysis of the depth measurement. 
 
Figure 12: µ-CT image of a microdialysis experiment with an application site of 1 cm². The membrane depth is shown in inverse 
color, with the membrane (M) in purple. 
 
M 
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5.3.3.2 Measurement via ultrasound 
The depth of the linear probe was determined with the Vevo 3100 from FujiFilm Visualsonics (Toronto, 
Canada). The skin was covered with Aquasonic 100 gel from Parker Laboratories (Fairfield, USA) and 
the lead wire was detected with the MX700 ultrasound transducer from FujiFilm Visualsonics (Toronto, 
Canada) inside the skin with a precision of 13 µm. The Vevo LAB3.1.1 software from FujiFilm 
Visualsonics (Toronto, Canada) was used to perform the analysis of the depth measurement. 
 
Figure 13: Ultrasound image of a microdialysis experiment with an application site of 1 cm². The membrane depth is shown 
in black white image, with the membrane (M) in white. 
 
5.3.3.3 Measurement via microscope 
For the depth determination images of the MD probes the porcine skin tissue was separated from the 
cartilage and the application area was cut into 0.5 x 1 cm stripes. The tissue samples were embedded 
in paraffin and the tissue sectioning and staining protocol was used as described in 5.2.8. 
M 
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Figure 14: HE image of a microdialysis experiment with an application site of 1 cm². The membrane depth is shown as a HE 
image, with the membrane (M) core. 
 
5.3.4 Absolute recovery (AR) 
The maximum absorption capacity of the unbound active compound to the microdialysis membranes 
was determined as in vitro absolute recovery. The AR was performed at the experimental flow rates of 
the microdialysis membrane experiments with 3 µL/min. The experiments were performed by 
inserting the membrane inside of a universal tube. The membranes were perfused with PBS as 
perfusion fluid. Samples were collected every 30 min for 2 h and analyzed by HPLC. For each time point, 
the AR was defined as ratio of the concentration of active in the dialysate and the concentration of 
active in the surrounding medium. 
 
 
Figure 15: Experimental setup to determine the absolute recovery. The membrane (M) is placed inside the universal tube 
containing the API formulation which and the API is collected in the sampling tube (Sample). 
 
M 
M 
API Formulation 
Sample 
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𝐴𝑅(in 𝑣𝑖𝑡𝑟𝑜) =  
(𝐶𝑑𝑖𝑎𝑙𝑦𝑠𝑎𝑡𝑒 − 𝐶𝑝𝑒𝑟𝑓𝑢𝑠𝑎𝑡𝑒)
(𝐶𝑚𝑒𝑑𝑖𝑢𝑚 − 𝐶𝑝𝑒𝑟𝑓𝑢𝑠𝑎𝑡𝑒)
∗ 100 
as Cperfusate = 0 
𝐴𝑅(in 𝑣𝑖𝑡𝑟𝑜) =  
(𝐶𝑑𝑖𝑎𝑙𝑦𝑠𝑎𝑡𝑒)
(𝐶𝑚𝑒𝑑𝑖𝑢𝑚)
∗ 100 
 
ARin vitro represents the absolute recovery in vitro; Cdialysate represents the active concentration in the 
dialysate; and Cmedium represents the active concentration in the surrounding medium. 
 
5.3.5 Skin recovery (SR) 
The maximum absorption capacity of the membrane inside the skin was tested with a formulation 
containing the active injected close to the membrane beneath the skin to float the skin with the 
formulation. The skin or ex vivo recovery was performed at the experimental flow rates of the 
microdialysis membrane experiments with 3 µL/min. The membranes were perfused with PBS as 
perfusion fluid. Samples were collected every 30 min for 2 h and analyzed by HPLC. For each time point, 
the SR was defined as ratio of the concentration of active in the dialysate and the concentration of 
active in the surrounding medium. 
 
Figure 16: Experimental setup of the SR with the injection sites (X) and the membrane inside the tissue (M), which collects 
the API inside the sampling tube (Sample). 
 
𝑆𝑅(𝑒𝑥 𝑣𝑖𝑣𝑜) =  
(𝐶𝑑𝑖𝑎𝑙𝑦𝑠𝑎𝑡𝑒 − 𝐶𝑝𝑒𝑟𝑓𝑢𝑠𝑎𝑡𝑒)
(𝐶𝑚𝑒𝑑𝑖𝑢𝑚 − 𝐶𝑝𝑒𝑟𝑓𝑢𝑠𝑎𝑡𝑒)
∗ 100 
as Cperfusate = 0 
𝑆𝑅(𝑒𝑥 𝑣𝑖𝑣𝑜) =  
(𝐶𝑑𝑖𝑎𝑙𝑦𝑠𝑎𝑡𝑒)
(𝐶𝑚𝑒𝑑𝑖𝑢𝑚)
∗ 100 
 
X 
X 
M 
Sample 
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SRin vitro represented the recovery ex vivo; Cdialysate represented the active concentration in the dialysate; 
and Cmedium represented the active concentration in the surrounding medium. 
 
 Static lateral penetration setup 
For the lateral penetration setup, the porcine ear was pinned dermal side down to a solid surface and 
the hair was cut manually. The application site was defined by a 1 cm² window color fence and 
10 µL/cm² of caffeine or LIP1 in a PGOA formulation were topically applied and penetrated the skin for 
4 h. The tissue was removed from the cartilage and a 4 cm² with the application site in the center was 
punched out. From the 4 cm² tissue the 1 cm² application site was punched out. The E and D were 
separated like described in 5.2.7. 
 
Figure 17: Experimental setup with 1 cm² application site (solid) and the 4 cm² lateral (dotted) penetration site. 
 
 High-Performance Liquid Chromatography (HPLC)  
The caffeine and LIP1 concentration were determined using HPLC (VWR-Hitachi ELITE LaChrom 
system). The quantity of caffeine was detected at a wavelength of 272 nm and for LIP1 at 285 nm with 
a DAD l-2450 detection unit and a column temperature of 30°C. The analytical determination was 
performed using a Chromolith ® Performance RP-18e 100-4.6 mm (Merck KGaA, Darmstadt) column as 
the stationary phase. The results for caffeine were obtained with a flow rate of 2.0 mL/min and an 
isochratic method with a mobile phase of 90 % water (Milli-Q®) and 10 % acetonitrile (HPLC gradient 
grade, Merck KGaA, Darmstadt). For LIP1, a flow rate of 2.0 mL/min for the isochratic method with 
80 % water and 20 % acetonitrile was used. 
Prior to the analysis, the samples were mixed and transferred into auto sampler screw micro-vials 
(VWR) and analyzed with an injection volume of 10-90 µL of each sample. The chemical stability was 
confirmed by analyzing the caffeine samples after 7 days at latest. The specificity of the HPLC run was 
controlled with a blank injection as an internal standard. 
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 HPLC data analysis 
The flux was calculated by the area under the curve from HPLC analysis data with the slope of the 
calibration curve and with respect to the volume of the receptor chamber and the applied membrane 
area of each diffusion cell for the FDC setup. For the MD setup, the perfusate and amount (in µg) of 
active ingredient were detected. 
 
 Calculation 
The drug amounts of all samples were calculated as follows. The quantification linearity for the active 
ingredient was confirmed by measuring a dilution series of an active standard solution of 0.5-
250.0 μg/mL. A graphic linear regression conformation was determined by monitoring the regression 
factor, which was found to be R2 > 0.99 in all cases. Accuracy and precision of the HPLC run was 
determined within the acceptance criteria of a variation of less than 2 %. 
 
𝑦 = 𝑚𝑥 + 𝑏 with b = 0 
Resulting in 𝐴 = 𝑚𝑐  
(A = area under the curve [AU], m = slope, c = concentration [µg/mL]) 
Calculating the concentration with: 𝑐 =
𝐴
𝑚
 [µg/mL] 
 
And further the total mass of penetrated active: 𝑚 = 𝑐 ∗ 𝑉 [µg] 
(V = volume in which the active was solved) 
 
Using the application area of each FDC, the cumulative amount Q of penetrated drug can be calculated:  
𝑄 =
𝑐
𝐴𝐹𝐷𝐶
 [µg/cm²] 
 
The drug amount per mass of skin layer, and for the finite experiments the amount of drug as a 
percentage of the applied amount, were determined.  
All calculations were made using the software program Microsoft® Excel® Office 365 and GraphPad 
Prism 8.03. 
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 Statistical analysis 
Statistical analysis was performed using GraphPad Prism 7.03 (GraphPad Software, San Diego, USA). 
All the data are shown as the mean ± SD. The statistical analyses were performed using t-tests or one-
way ANOVA statistics (the Bonferroni method for multiple comparisons was also applied). Probability 
(p) values less than 0.05 were considered statistically significant. 
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6 Results 
For the penetration abilities of APIs, caffeine and LIP1 were tested for their target-site penetration into 
skin. These APIs were chosen since they have different physico-chemical characteristics and are tested 
in an FDC and MD setup in finite and infinite dosage forms using different formulations. 
 Validation of the FDC system 
In the experimental percutaneous skin penetration setup, the influences of different human skin 
surrogates, changes to the fluid in the donor chamber, and different receptor chamber conditions are 
tested. Influences on the penetration of the model active, caffeine, for topical application are shown. 
The standard penetration flux was determined for an infinite (786 µL/cm²) dosage of 0.7 % caffeine 
formulation on different skin surrogates. For ex vivo human and porcine split-skin penetration studies 
of 500 µm thick split-skin was used. 
6.1.1 Human skin surrogate comparison 
To study skin penetration, ex vivo human and porcine split-skin was used. For the in vitro penetration 
study, the artificial membrane, Strat-M®, was used as a surrogate for human skin. 
6.1.1.1 Validation of the skin surrogate and determine the effect of the operator 
Skin thickness on penetration testing in the FDC 
 
 
Figure 18: Schematic illustration of the skin disc thickness measurement (A). Determination of the thickness of dermatomed 
skin discs (B). Comparison of micrometer measurements of skin determined four peripheral measurement sites (blue) vs a 
central measurement site (black). Values represent mean (n = 16) ± SD, compared using t-Test statistics. 
A B 
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Figure 18 shows the comparability of the thickness of dermatomized skin by the measurement of four 
sites of the skin disc and the middle of the disc. The mean measurements of the middle with 
330 ± 60 µm had no statistically significant differences than 315 ± 55 µm for the measurement sites. 
 
Table 4: Defined dermatomized thickness of skin disc and mean thickness of each skin layer. 
Thickness setting on 
dermatome [µm] 
Skin layer Measured thickness of 
skin layer [µm] 
 
SC 12.05 ± 2.70 
300 E 101.6 ± 34.2 
 
D 180.4 ± 86.4 
 
SC 12.3 ± 3.2 
500 E 105.3 ± 27.5 
 
D 488.3 ± 110.9 
 
SC 9.9 ± 0.8 
700 E 111.8 ± 24.6 
 
D 702.5 ± 99.20 
 
SC 14.6 ± 3.9 
1000 E 124.3 ± 46.7 
 
D 970.8 ± 203.9 
 
The defined dermatome thickness setting of 300, 500, 700 and 1000 µm was tested and the mean 
thickness of each skin layer was determined. For each defined thickness the mean SC was between 
9.1 µm and 18.5 µm and the E between 77.6 µm and 171 µm thick. The D layer was progressively 
thicker from the thinnest dermatomed skin disc to the thickest, ranging from 94 to 1174.7 µm. Split-
skin comprises always the SC and E plus an increasing thickness of the D depending of the dermatomed 
split-skin thickness. 
To validate the integrity of the different skin layers the TEWL was measured. 
 
TEWL integrity determination 
To determine the integrity of the skin surrogates the TEWL was measured for the Stat-M membrane, 
the porcine and human split-skin. 
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Figure 19: TEWL of different human skin surrogates. The TEWL of the Strat-M® membrane (A) (n = 24), 500 µm porcine split-
skin (B) (n = 30) and 500 µm human split-skin (C) (n = 30) mounted on a FDC was determined with a TEWL device. Values 
represent mean ± SD. 
In Figure 19 the mean TEWL of the Strat-M® membrane, porcine, and human split-skin were 
determined to be 20 ± 1, 14 ± 6 and 12.5 ± 3.5 g/m2/h, respectively. Therefore, the SD for the TEWL 
measurements was Strat-M®< porcine skin< human skin.  
The influence of the thickness on the TEWL of the skin was measured for 300 to 1000 µm thick porcine 
split-skin. 
B A 
C 
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Figure 20: Correlation of TEWL vs skin thickness. Measured TEWL values are plotted against the measured thickness of porcine 
split-skin obtained using the dermatome setting 300 µm (blue), 500 µm (black), 700 µm (grey) and 1000 µm (light grey). m = 
-0.0156, R2 = 0.4589 (n = 12). 
Figure 20 shows the TEWL values from dermatomed porcine split-skin obtained at settings of 300, 500, 
700 and 1000 µm which was measured for its thickness. With an increase in skin thickness, lower TEWL 
values and a downward trajectory of the linear regression is observed. Similarly, thicker sections 
appear to show a lower SD than thinner sections.  
Due to biological variations from donor to donor and experiment to experiment the variations range 
was determined. 
 
6.1.1.2 Experimental variation of the in vitro and ex vivo penetration testing of caffeine 
 
B A 
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Figure 21: Experimental variation of different human skin surrogates. The experimental variation and the caffeine flux through 
the Strat-M® membrane (A), 500 µm human split-skin (B) and porcine split-skin (B) mounted on the FDC was determined. 
Each bar represents the caffeine penetration flux for six replicates (n = 6) from a single donor for 4 h at 32°C and a topical 
application of 786 µL 0.7 % caffeine PGOA formulation. The caffeine flux through the porcine split-skin shows the inter (C) 
and intra (D) biological variance. Values represent mean ± SD, compared using one-way ANOVA statistics. 
Figure 21 illustrates the biological variation of different skin surrogates, where 1172 to 1247 µg/cm² 
caffeine penetrated through the Strat-M® membrane. 121 to 207 µg/cm² caffeine penetrated through 
the porcine skin and 0.35 to 0.77 µg/cm² through the human skin. All similar surrogates show no 
statistically significant difference for the experiments. The SD regarding the measured penetration 
experiments was lowest for Strat-M®, intermediate for human skin and highest for porcine skin. 
6.1.1.3 Impact of kinetic sampling on absolute caffeine concentration in the FDC 
The impact of different sampling techniques, of individual experiments per time point and cumulative 
sampling for 1 h and 2 h was determined for kinetic penetration experiments on different human 
surrogates. 
 
Figure 22: Kinetic caffeine flux through the Strat-M® membrane. The caffeine flux through the Strat-M® membrane for 10 h at 32°C 
for a topical application of 786 µL 0.7 % caffeine PGOA formulation was determined. Within the blue line every time point represents 
the caffeine penetration flux for six replicates (n = 6) of individual experiments. The grey and black line represents the caffeine 
penetration flux for six replicates (n = 6) for one experiment with 1 h and 2 h cumulative sampling, respectively. Values represent 
mean ± SD, compared using one-way ANOVA statistics. 
C D 
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Figure 22 shows the kinetic caffeine flux through the Strat-M® membrane. The experiments show a 
similar kinetic with no statistically significant differences regardless if single experiments or cumulative 
sampling for 1 h or 2 h were performed. Over 10 h a hyperbolic curve with a caffeine maximum of 2105 
to 2296 µg/cm² with a range difference of 191 µg/cm², which is 12 % of the maximum, was observed. 
After 4 h the caffeine flux of 1230 to 1261 µg/cm² with a range difference of 31 µg/cm², which is 2 %, 
was observed. The maximum amount of caffeine that penetrated the Strat-M® membrane after 4 h is 
55 % of the maximum after 10 h. 
 
Figure 23: Kinetic caffeine flux through porcine skin. The caffeine flux through 500 µm porcine split-skin for 10 h at 32°C and a topical 
application of 786 µL 0.7 % caffeine PGOA formulation was determined. Within the blue line every time point represents the caffeine 
penetration flux for six replicates (n = 6) of individual experiments. The grey and black line represents the caffeine penetration flux 
for six replicates (n = 6) for one experiment with 1 h and 2 h cumulative sampling, respectively. Values represent mean ± SD, 
compared using one-way ANOVA statistics. 
Figure 23 shows the kinetic caffeine flux through 500 µm porcine split-skin. The experiments show a 
similar kinetics and no statistically significant differences were found between independent single 
sampling or cumulative sampling for 1 h or 2 h. Over 10 h a hyperbolic curve with a caffeine maximum 
of 636 to 830 µg/cm² with a range difference of 194 µg/cm², which is 24 % of the maximum, was 
observed. After 4 h the caffeine flux of 98 to 204 µg/cm² with a range difference of 106 µg/cm², which 
is 52 %, was observed. The maximum amount of caffeine that penetrated the porcine skin after 4 h is 
25 % of the maximum after 10 h. 
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Figure 24: Kinetic caffeine flux through human skin. The caffeine flux through 500 µm human split-skin for 10 h at 32°C and a 
topical application of 786 µL 0.7 % caffeine PGOA formulation was determined. The blue line represents the caffeine 
penetration flux for six replicates (n = 6) for one experiment with 1 h cumulative sampling. The grey and black line represent 
the caffeine penetration flux for two donors with six replicates (n = 6) for one experiment with 2 h cumulative sampling. 
Values represent mean ± SD, compared using one-way ANOVA statistics. 
Figure 24 shows the kinetic caffeine flux through 500 µm human split-skin. The experiments show a 
similar kinetic trend with no statistically significant differences for independent cumulative sampling 
or cumulative sampling every 1 h or 2 h. Over 10 h a beginning exponential curve with a caffeine 
maximum of 11 to 31 µg/cm² with a range difference of 20 µg/cm², which is 65 % of the maximum, 
was observed. After 4 h the caffeine flux of 0.08 to 1.9 µg/cm² with a range difference of 1.82 µg/cm², 
which is 96 %, was observed. The maximum amount of caffeine that penetrated the human skin after 
4 h is 6 % of the maximum after 10 h. 
 
Figure 25: Kinetic caffeine flux through different human skin surrogates. The caffeine flux through Strat-M®, porcine and 
human split-skin for 10 h at 32°C and a topical application of 786 µL 0.7 % caffeine PGOA formulation was determined. The 
blue line represents the mean caffeine penetration flux through the Strat-M® membrane (n = 18). The grey line represents 
the mean caffeine penetration flux for three donors with six replicates (n = 18) through 500 µm porcine split-skin and black 
line represent the mean caffeine penetration flux for three donors with six replicates (n = 18) for through 500 µm human 
split-skin. Values represent mean ± SD. 
Figure 25 shows caffeine flux over 10 h through the Strat-M® membrane, 500 µm porcine split-skin, 
and 500 µm human split-skin. The penetration kinetics through the Strat-M® membrane and porcine 
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skin show a hyperbolic curve with a maximum of 2192 µg/cm² and 779 µg/cm² after 10 h. Strat-M® has 
a 2.8-fold penetration compared to porcine skin. Human skin shows after 10 h a flux of 22 µg/cm² 
which is 100-fold less than Strat-M® and 35-fold less than porcine skin. For the membrane the half 
maximum caffeine flux was reached after 3.5 h, for porcine skin after 6.3 h and for human skin after 
8.3 h. 
6.1.2 Influences of donor chamber conditions 
For percutaneous penetration studies, the API vehicle, the API concentration and the amount of 
applied formulation are essential. The influences of the donor chamber conditions with a change in 
formulation, volume and concentration were tested for a topical application of caffeine at 32°C for 4h. 
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6.1.2.1 Effect of the formulation on the penetration 
The influences of a 0.7 % caffeine PGOA, PG and H2O formulation on the penetration through the Strat-
M® membrane, porcine and human split-skin were determined. 
 
 
Figure 26: Influences of the formulation on the caffeine flux through different human skin surrogates. The PGOA, PG and H2O 
caffeine formulations and the caffeine flux through the Strat-M® membrane (A), 500 µm porcine split-skin (B) and 500 µm 
human split-skin (C) mounted on the FDC were determined. Each bar represents the caffeine penetration flux for six replicates 
(n = 6) from a single donor for 4 h at 32°C and a topical application of 786 µL and a 0.7 % caffeine formulation. Values 
represent mean ± SD. 
Figure 26 shows the influences on the penetration of different caffeine formulations on Strat-M® 
membrane, porcine split-skin, and human split-skin. The penetration and flux of caffeine was for Strat-
M® membrane > porcine skin > human skin. In a PGOA formulation caffeine penetrated the Strat-M® 
membrane 3.6-fold more the than the PG formulation and 15.6-fold more than the water formulation. 
The concentration of penetrated caffeine with the PGOA resulted in 19.2-fold higher flux than the PG 
formulation and 33-fold higher compared to the water formulation through porcine skin. For human 
skin, caffeine penetrated using a PGOA formulation 77.6-fold higher than for the PG formulation and 
500-fold compared to the water formulation. The SD of the penetration experiments was for Strat-M® 
membrane < human skin < porcine skin. 
A B 
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6.1.2.2 Effect of the donor volume on penetration 
The influences of a 0.7 % caffeine PGOA formulation topically applied in a finite (<100 µL/cm²) and 
infinite (>100 µL/cm²) amount on the penetration through the Strat-M® membrane and porcine split-
skin was determined. 
 
Figure 27: Influences of the volume amount on the caffeine flux through different human skin surrogates. The influences of 
different volumes and the caffeine flux through the Strat-M® membrane and 500 µm porcine split-skin mounted on the FDC 
were determined. Each volume represents the caffeine penetration flux for six replicates (n = 6) from a single donor for 4 h 
at 32 and a topical application of a 0.7 % caffeine PGOA formulation. Values represent mean ± SD. 
Figure 27 shows the influences on the caffeine penetration of different formulation volumes on the 
Strat-M® membrane and porcine split-skin. Caffeine penetrated with a linear flux through the Strat-M® 
membrane up to a volume of 100 µL and penetrated with a volume > 100 µL in hyperbolic flux until a 
plateau was reached. For the porcine skin caffeine penetrated with a linear correlation of volume and 
flux up to 1000 µL. With a topical application of 1000 µL, 1380 µg/cm² caffeine penetrated the Strat-
M® membrane and 411 µg/cm² the porcine skin. The SD of the penetration experiments was less for 
Strat-M® than for porcine skin. 
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6.1.2.3 Effect of caffeine saturation on penetration  
The influences of the saturation of caffeine in a PGOA formulation topically applied on the penetration 
through the Strat-M® membrane and porcine split-skin was determined. 
 
 
Figure 28: Influences of the caffeine saturation on the caffeine flux through different human skin surrogates. The influences 
of caffeine saturation and the caffeine flux through the Strat-M® membrane and 500 µm porcine split-skin mounted on the 
FDC were determined. Each saturation concentration represents the caffeine penetration flux for six replicates (n = 6) from a 
single donor for 4 h at 32°C and a topical application of 786 µL/cm² of a caffeine PGOA formulation. Values represent mean 
± SD. 
Figure 28 shows the influences on the caffeine penetration of different caffeine concentrations on the 
Strat-M® membrane and porcine split-skin. Caffeine penetrated with a linear correlation to the 
concentration, with 100% of saturation 6.4-fold through the Strat-M® membrane compared to the 
porcine split-skin. The SD of the penetration experiments was less for Strat-M® compared to porcine 
skin. 
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6.1.3 Influences of receptor chamber conditions 
To study the percutaneous skin penetration ex vivo porcine skin was used. For the in vitro penetration 
study, the artificial Strat-M® membrane was used as a surrogate for human skin. The influences of the 
receptor chamber with a change in temperature and receptor fluid were tested for a topical application 
of a saturated caffeine PGOA formulation for 4 h at 32°C. 
6.1.3.1 Effect of the temperature on the penetration 
The influences of the receptor fluid temperature on the caffeine flux in a PGOA formulation topically 
applied on the penetration through the Strat-M® membrane and porcine split-skin are determined. 
 
Figure 29: Influences of the receptor fluid temperature on the caffeine flux through different human skin surrogates. The 
influence of the receptor chamber temperature on the caffeine flux through the Strat-M® membrane and 500 µm porcine 
split-skin mounted on the FDC were determined. Each temperature represents the caffeine penetration flux for six replicates 
(n = 6) from a single donor for 4 h at 32°C and a topical application of 786 µL/cm² of a 0.7 % caffeine PGOA formulation. 
Values represent mean ± SD. 
Figure 29 shows the influences on the caffeine penetration of different receptor chamber 
temperatures on the Strat-M® membrane and porcine split-skin. Caffeine penetrated with a linear flux 
5-fold more through the Strat-M® membrane than through porcine skin. At 37°C 1650 µg/cm² caffeine 
penetrated through the Strat-M® membrane and 330 µg/cm² through porcine skin. The SD of the 
penetration experiments was less for Strat-M® than for porcine skin. 
6.1.3.2 Effect of the receptor fluid on the penetration 
The influences of multiple receptor fluids which are used for lipophilic APIs were tested on their 
penetration influences for the caffeine flux in a PGOA formulation topically applied through the Strat-
M® membrane and porcine split-skin. 
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Figure 30: Influences of the receptor fluid on the caffeine flux through the Strat-M® membrane. The influence of the receptor 
fluid on the caffeine flux through the Strat-M® membrane mounted on the FDC were determined. Each bar represents the 
caffeine penetration flux for six replicates (n = 6) for 4 h at 32°C and a topical application of 786 µL/cm² of a 0.7 % caffeine 
PGOA formulation. With PBS++ (with Mg2+ and Ca2+), PBS-- (without Mg2+ and Ca2+), H2O (Milli-Q), BSA (1 % BSA and 0.9 % 
NaCl in H2O), B 5 % (Brij 5 % in H2O) and CD 5 % (Cyclodextrin 5 % in PBS++) in the receptor chamber. Values represent mean 
± SD, compared using one-way ANOVA statistics. 
Figure 30 shows the influence on the caffeine penetration through the Strat-M® membrane for different 
receptor fluids. Between 1253 µg/cm² and 1477 µg/cm² caffeine penetrated through the membrane, 
therefore PBS++ showed the lowest and 5 % Cyclodextrin in PBS++ the highest penetration flux as a receptor 
fluid. The receptor fluids PBS--, H2O, BSA, B 5 % and CD 5 % show no statistically significant differences. 
 
Figure 31: Influences of the receptor fluid on the caffeine flux through the 500 µm porcine split-skin. The influence of the 
receptor fluid on the caffeine flux through 500 µm porcine split-skin mounted on the FDC were determined. Each bar 
represents the caffeine penetration flux for six replicates (n = 6) from a single donor for 4 h at 32°C and a topical application 
of 786 µL/cm² of a sat. caffeine PGOA formulation. With PBS++ (with Mg2+ and Ca2+), PBS-- (without Mg2+ and Ca2+), H2O (Milli-
Q), BSA (1 % BSA and 0.9 % NaCl in H2O), B 5 % (Brij 5 % in H2O) and CD 5 % (Cyclodextrin 5 % in PBS++) in the receptor 
chamber. Values represent mean ± SD, compared using one-way ANOVA statistics. 
Figure 31 shows the influence on the caffeine penetration through porcine skin for different receptor fluids. 
PBS-- and H2O show with 52 µg/cm² and 71 µg/cm² the lowest and therefore the baseline amount of 
penetrated caffeine 5 % CD in PBS shows with 257 µg/cm² the highest penetration flux. The receptor fluids 
PBS++, BSA, B 5 % and CD 5 % show no statistically significant differences.  
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 Influences of the API lipophilicity on penetration 
For the experimental skin penetration setup and an understanding of the influences of molecular 
weight and lipophilicity ex vivo porcine skin was used. Caffeine as a hydrophilic active and the lipophilic 
active LIP1 have the identical molecular weight and are tested for their penetration ability in different 
skin layers. The influences on the penetration for topical application of a finite (10 µL/cm²) and infinite 
(786 µL/cm²) amount with 0.7 % active in a PG and PG with 5 % OA formulation were tested. 
6.2.1 Skin penetration using the FDC setup  
For the ex vivo percutaneous penetration studies 500 µm porcine split-skin was mounted on the FDC 
filled with PBS++ at 32°C. Therefore, the penetration features into the SC, viable epidermis (E) and 
dermis (D) of caffeine and LIP1 for a PG and PGOA formulation were tested as well as their ability of 
lateral penetration. 
6.2.1.1 Effect of the skin thickness on the penetration 
  
Figure 32: Influences of the different skin layers on the caffeine flux through porcine split-skin. The influences of the E and SC 
removal of 500 µm split-skin and different split-skin thicknesses on the caffeine (A) and LIP1 (B) flux through porcine split-
skin mounted on the FDC were determined. Each bar represents the caffeine or LIP1 penetration flux for six replicates (n = 6) 
from a single donor for 4 h at 32°C and a topical application of 10 µL/cm² of a caffeine or LIP1 PGOA formulation. Values 
represent mean ± SD, compared using t-Test statistics. 
Figure 32 shows the influences on the caffeine and LIP1 penetration for different split-skin thicknesses. 
Additionally, the removal of the E and SC on 500 µm thick porcine split-skin was tested for the 
penetration ability of caffeine. Caffeine penetrated the skin with the lowest flux of 19 µg/cm² up to 
67 µg/cm². Depending on the D thickness, between 19 to 31 µg/cm² caffeine penetrated the skin with 
a low gradient. The removal of the E in contrast to the SC removal increased the flux 1.18-fold. Due to 
the SC removal 1.84-fold more caffeine penetrated through the skin which is an increase of 84 % on 
the penetration. LIP1 penetrated the skin with the lowest flux of 4 µg/cm² up to 49 µg/cm². Depending 
A B 
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on the D thickness, between 4 to 25 µg/cm² LIP1 penetrated the skin with a high gradient. The removal 
of the E in contrast to the SC removal increased the flux 1.12-fold. Due to the SC removal 1.74-fold 
more LIP1 penetrated through the skin which is an increase of 74 % on the penetration. The removal 
of the lipophilic SC had a statistically significant influence on the penetration on the hydrophilic 
caffeine but not for lipophilic LIP1. The influences of the different skin layers on the penetration of 
caffeine and LIP1 are shown in Figure 32 but the understanding of the total amount of API in the 
different layers and amount per skin layer weight is missing. 
6.2.1.2 Skin layer dependent penetration 
For the experimental percutaneous skin penetration setup, the influences of different skin layers (SC, 
E and D) on the lipophilicity of the API were tested. The influences of the formulation (PG/PGOA), 
application volume (10/786 µL/cm²) and kinetics are shown. For the ex vivo penetration study 500 µm 
porcine split-skin was used and experiments with a total recovery ≥ 70 % are shown in percentage of 
total active determined. Therefore, the amount of the active found in the different layers is defined as 
lateral (Lateral), SC, E, and D penetration as well as active which did not penetrate (SW) and active 
which penetrated the whole skin inside the receptor fluid (RF). 
6.2.1.3 Penetration kinetics for a finite applied volume of different formulations 
The influences of the lipophilicity of caffeine and LIP1 for finite application of PG and PGOA formulation 
were tested. 
 
Figure 33: Influences of the API and the formulation on the penetration. The kinetic penetration of caffeine (blue) and LIP1 
(red) through 500 µm porcine split-skin for 1 h, 4 h and 20 h at 32°C was determined. Every time point represents the 
penetration flux for six replicates (n = 6) from a single donor for a topical application of 10 µL/cm² of 0.7 % active in a PG 
(lighter) or PGOA (darker) formulation. Values represent mean ± SD. 
Figure 33 shows the caffeine and LIP1 penetration flux for a finite topical application of a PG and PGOA 
formulation over time through porcine skin. The penetration of the active into the skin was increased 
 Dissertation I Markus Lubda I Results  54 
using PG with OA. Caffeine penetrated the skin more efficiently compared to LIP1 for the PG and PGOA 
formulation, except for the PGOA formulation after 20 h. After 4 h caffeine penetrated within the 
PGOA formulation the skin with 31 µg/cm² 1.9-fold and after 20 h 0.96-fold of LIP1. For the PG 
formulation, caffeine penetrated the skin after 20 h 2.8-fold more and LIP1 10.5-fold more. 
  
Figure 34: Influences of the API in a PG formulation on the penetration. The mean distribution of caffeine (A) and LIP1 (B) in 
the SC, E and D of 500 µm porcine split-skin after 1 h, 4 h and 20 h at 32°C was determined. A finite dose of 10 µL/cm² of 
0.7 % active solved in a PG formulation was topically applied. Each bar shows the percentage of determined active in each 
layer (Lateral, SW, SC, E, D and RF) and represents the penetration for six replicates (n = 6) from a single donor. Values 
represent mean ± SD and a total recovery of the API > 70 % of the application amount. 
Figure 34 shows the penetration of caffeine and LIP1 for a finite topical application of a PG formulation. 
The figure shows an increase of caffeine and LIP1 in the RF and a decrease in the SW over time with a 
higher amount and faster penetration for caffeine. After 4 h and 20 h, 7 % and 40 % of determined 
caffeine and after 20 h 13 % of the determined LIP1 penetrated into the RF. Caffeine penetrates the 
skin in deeper skin layers (E and D) faster and with a higher amount than LIP1. The lateral penetration 
increases over time for both actives and especially caffeine shows with 50 % of the determined active 
a higher lateral penetration after 20 h. For LIP1 the SC is the main reservoir of the different skin layers 
and for every time point the highest amount of determined active inside the skin, after 1 h 27 %, after 
4 h 23 % and after 20 h 26 %. 
 
A B 
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Figure 35: Influences of the API in a PGOA formulation on the penetration. The mean distribution of caffeine (A) and LIP1 (B) within 
the SC, E and D of 500 µm porcine split-skin after 1 h, 4 h and 20 h at 32°C was determined. A finite dose of 10 µL/cm² of 0.7 % active 
solved in a PGOA formulation was topically applied. Each bar shows the percentage of determined active in each layer (Lateral, SW, 
SC, E, D and RF) and represents the penetration for six replicates (n = 6) from a single donor. Values represent mean ± SD and a total 
recovery of the API > 70 % of the application amount. 
Figure 35 shows the penetration of caffeine and LIP1 for a finite topical application of a PGOA 
formulation. The figure shows an increase of caffeine and LIP1 in the RF and a decrease in the SW over 
time with a higher amount and faster penetration for caffeine. After 20 h 98 % of determined caffeine 
and 93 % of determined LIP1 was located in the RF. Caffeine penetrates the skin in deeper skin layers 
(E and D) within 1 h with a higher amount than LIP1. The total determined API which penetrated lateral 
increases over time for both actives but remains constant with ~20 % of the determined caffeine and 
with 10-12 % of the determined LIP1 for 1 h and 4 h experiments. For LIP1 the SC is the main reservoir 
of the different skin layers and for every time point the highest amount of determined active inside 
the skin, after 1 h 36 %, after 4 h 35 % and after 20 h 5 %. 
 
Figure 36: The mean amount of caffeine (blue) and LIP1 (red) per skin layer within the SC, E and D of 500 µm porcine split-skin after 
1 h, 4 h and 20 h at 32°C was determined. A finite dose of 10 µL/cm² of 0.7 % active solved in a PGOA formulation was topically 
applied. Each bar shows the amount of mass per skin layer (SC, E and D) and represents the penetration for six replicates (n = 6) from 
a single donor. Values represent mean ± SD and a total recovery of the API > 70 % of the application amount. 
A B 
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Figure 36 shows the mean amount of caffeine and LIP1 which penetrated in the different skin layers 
for a finite topical application of a PGOA formulation for a kinetic of 1 h, 4 h and 20 h. The SC, E and D 
layers show for each time point the similar increase and decrease trend and an equilibrium distribution 
for each layer of the total determined active amount. Except for the amount of caffeine and LIP1 in 
the SC after 1 h, there is a higher amount than for other time points and skin layer correlations. The 
amount of caffeine and LIP1 per skin layer is for the SC< E< D for every time point. 
6.2.1.4 Penetration differences for biological variation for a finite formulation volume 
  
Figure 37: The mean distribution of caffeine (A) and LIP1 (B) within the SC, E and D of 500 µm porcine split-skin for three 
different donors was determined. A finite dose of 10 µL/cm² of 0.7 % active solved in a PGOA formulation was topically 
applied for 4h at 32°C. Each bar shows the percentage of determined active in each layer (Lateral, SW, SC, E, D and RF) and 
represents the penetration for six replicates (n = 6) from a single donor. Values represent mean ± SD and a total recovery of 
the API > 70 % of the application amount. 
Figure 37 shows the mean distribution of caffeine and LIP1 within the different layers of skin for a finite 
topical application of a PGOA formulation for three donors. For all three donors the distribution of 
caffeine inside the RF is with > 50 % higher than for LIP1 with 38-42 %. The skin layers show a higher 
distribution of caffeine inside the SC> D> E, this is similar for LIP1 except that the SC shows with 23-
39 % of determined LIP1 a higher amount of active. LIP1 shows for each donor 2-3 % of active inside 
the E and 6-8 % inside the D layer. The receptor chamber shows for the LIP1 penetration for donor one 
with 42 % the highest amount of active for donor two and three the SC exhibits more active than the 
26-34 % of RF. The lateral penetration has with 17-23 % a higher distribution for the penetration of 
caffeine than with 7-15 % for LIP1 for all three donors.  
A B 
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Figure 38: The mean of the distribution of caffeine and LIP1 within the SC, E and D of 500 µm porcine split-skin porcine for 
three different donors was determined. A finite dose of 10 µL/cm² of 0.7 % active solved in a PGOA formulation was topically 
applied for 4 h at 32°C. Each bar shows the percentage of determined active in each layer (Lateral, SW, SC, E, D and RF) and 
represents the penetration for six replicates (n = 6) from a single donor. Values represent mean ± SD and a total recovery of 
the API > 70 % of the application amount. 
Figure 38 shows the mean of the distribution of caffeine and LIP1 within the different layers of skin for 
a finite topical application of a PGOA formulation for three donors. After a penetration for 4 h caffeine 
was prominently determined inside the RF> Lateral> SC> SW> E> D. LIP1 follows the distribution of SC> 
RF> SW> Lateral> D> E. Inside the RF the caffeine amount is 1.6-fold higher than LIP1 and inside the SC 
LIP1 is 2.8-fold higher than caffeine. 
 
Figure 39: The mean amount of caffeine per skin layer within the SC, E and D of 500 µm porcine split-skin for three different 
donors was determined. A finite dose of 10 µL/cm² of 0.7 % active solved in a PGOA formulation was topically applied for 4 h 
at 32°C. Each bar shows the amount of absolute mass per skin layer (SC, E and D) and represents the penetration for six 
replicates (n = 6) from a single donor. Values represent mean ± SD and a total recovery of the API > 70 % of the application 
amount. 
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Figure 39 shows the mean amount of caffeine which penetrated in the different skin layers for a finite 
topical application of a PGOA formulation for three different donors. For each donor the highest 
amount of caffeine was found in the SC and the E shows a higher amount compared to the D, per mass 
of the skin layer. All three donors show an intra-donor equilibrium and a donor-specific trend for the 
different skin layers (Table 5). The concentration of active ingredient that penetrated into the E and D 
corelated with the amount of active ingredient in the SC for a specific donor. The trend if and how 
much caffeine penetrated each skin layer shows a similar correlation for each donor. 
Table 5: Amount of caffeine per skin layer weight for three donors inside the SC, E, D, E/D and SC/E/D. 
 
 
 
 
 
 
 
Figure 40: The mean amount of LIP1 per skin layer within the SC, E and D of 500 µm porcine split-skin skin for three different 
donors was determined. A finite dose of 10 µL/cm² of 0.7 % active solved in a PGOA formulation was topically applied for 4 h 
at 32°C. Each bar shows the amount of absolute mass per skin layer (SC, E and D) and represents the penetration for six 
replicates (n = 6) from a single donor. Values represent mean ± SD and a total recovery of the API > 70 % of the application 
amount. 
Figure 40 shows the mean amount of LIP1 which penetrated in the different skin layers using a finite 
topical application of a PGOA formulation for three different donors. For each donor the highest 
Caffeine 
[µg/mg] Donor 1 Donor 2  Donor 3 
 
SC 5.14 9.85 11.36  
E 0.01 0.09 0.2  
D 0.02 0.05 0.11  
E/D 0.03 0.14 0.31  
SC/E/D 5.17 9.99 11.67  
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amount of LIP1 was determined in the SC and the E shows a higher amount than the D, per mass of 
the skin layer. All three donors show an intra-donor equilibrium for the different layers (Table 6). If in 
the SC a lower amount of active was determined in the E also a lower amount was found in the D of 
one donor, except for the D of donor three shows a lower amount of LIP1. The trend if and how much 
caffeine penetrated each skin layer shows a similar correlation for each donor. 
Table 6: Amount of LIP1 per skin layer weight for three donors inside the SC, E, D, E/D and SC/E/D. 
 
 
 
 
 
 
 
 
Figure 41: The mean amount of caffeine (blue) and LIP1 (red) per skin layer within the SC, E and D of 500 µm porcine split-
skin skin for three different donors was determined. A finite dose of 10 µL/cm² of 0.7 % active solved in a PGOA formulation 
was topically applied for 4 h at 32°C. Each bar shows the amount of absolute mass per skin layer (SC, E and D) and represents 
the penetration for six replicates (n = 6) from a single donor. Values represent mean ± SD and a total recovery of the API > 
70 % of the application amount. 
Figure 41 shows the mean of caffeine and LIP1 amount within the different layers of skin for a finite 
topical application of a PGOA formulation for three donors. For both actives the SC> E> D amount of 
caffeine and LIP1. Caffeine shows a 87-fold higher amount in the SC than the E and the E a 1.7-fold 
higher amount than the D. LIP1 shows a 89-fold higher amount in the SC than the E and the E a 2.3-
fold higher amount than the D. Inside each layer a significant higher amount of LIP1 was determined 
LIP1 
[µg/mg] Donor 1 Donor 2 Donor 3 
SC 11.84 21.12 28.4 
E 0.12 0.2 0.37 
D 0.07 0.13 0.11 
E/D 0.19 0.33 0.48 
SC/E/D 12.03 21.45 28.88 
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compared to caffeine. The SC shows a 2.4-fold, the E a 2.3-fold and the D a 1.7-fold higher amount for 
LIP1 than caffeine. The SD of the E and D layer was higher than for the SC. 
 
Figure 42: The mean amount of caffeine (blue) and LIP1 (red) inside the SC of 500 µm porcine split-skin for three different 
donors was determined. A finite dose of 10 µL/cm² of 0.7 % active solved in a PGOA formulation was topically applied for 4 h 
at 32°C. Each bar shows the amount of absolute mass per skin layer (SC, E and D) and represents the penetration for six 
replicates (n = 6) from a single donor. Values represent mean ± SD and a total recovery of the API > 70 % of the application 
amount. 
Figure 42 shows the mean of caffeine and LIP1 amount within the SC for a finite topical application of 
a PGOA formulation for three donors. Inside the SC there was 8.6 µg/mg and 20.5 µg/mg per SC tissue 
found for caffeine and LIP1. LIP1 shows with a 2.4-fold penetration ability inside the SC a significant 
higher amount. 
6.2.1.5 Penetration kinetics for an infinite applied formulation volume 
 
Figure 43: The kinetic penetration of caffeine (blue) and LIP1 (red) through 500 µm porcine split-skin for 1 h, 4 h and 20 h at 
32°C was determined. Every time point represents the penetration flux for six replicates (n = 6) from a single donor for a 
topical application of finite (10 µL/cm²) or infinite (786 µL/cm²) of 0.7 % active in a PGOA formulation. Values represent mean 
± SD and a total recovery of the API > 70 % of the application amount. 
Figure 43 shows the kinetic penetration flux of caffeine and LIP1 for a finite and infinite topical 
application of a PGOA formulation over time through porcine skin. The penetration of the active into 
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the skin was increased by using an infinite amount of formulation. Caffeine penetrated for the first 4 h 
the skin in a higher amount than LIP1 for an infinite and finite application. After 4 h a higher amount 
of LIP1 penetrated through the skin for an infinite application than for the finite caffeine or LIP1 
application. Caffeine penetrated the skin with a flux of 1480 µg/cm² for an infinite and 58 µg/cm² for 
a finite application after 20 h. LIP1 penetrated the skin with a flux of 558 µg/cm² for an infinite and 
60 µg/cm² for a finite application after 20 h. After 20 h the infinite applied caffeine penetrated 2.7-fold 
higher than LIP1 and LIP1 1.1-fold higher than caffeine for a finite applied dose. 
  
Figure 44: The mean distribution of caffeine (A) and LIP1 (B) within the SC, E and D of 500 µm porcine split-skin after 1 h, 4 h 
and 20 h at 32°C was determined. An infinite dose of 786 µL/cm² of 0.7 % active solved in a PGOA formulation was topically 
applied. Each bar shows the percentage of determined active in each layer (Lateral, SW, SC, E, D and RF) and represents the 
penetration for six replicates (n = 6) from a single donor. Values represent mean ± SD and a total recovery of the API > 70 % 
of the application amount. 
Figure 44 shows the penetration of caffeine and LIP1 for an infinite topical application of a PGOA 
formulation. The figure shows an increase of caffeine and LIP1 in the RF over time with a higher amount 
and faster penetration for caffeine. After 20 h 96 % of determined caffeine and 92 % of determined 
LIP1 is located in the RF. Over time the amount of determined caffeine and LIP1 which penetrated the 
skin decreases inside the SC and E. For the 1 h and 4 h penetration experiment the determined amount 
of LIP1 is with 70 % and 61 % higher than the 63 % and especially the 31 % of caffeine. The determined 
amount of caffeine inside the D is with 36 % after 4 h higher than 15 % and 2 % after 1 h and 20 h. For 
LIP1 14 % was in the dermis after 4 h and after 1 h and 20 h 3 % and 5 % were determined. 
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Figure 45: The mean amount of caffeine (blue) and LIP1 (red) per skin layer within the SC, E and D of 500 µm porcine split-
skin after 4 h at 32°C was determined. An infinite (lighter) dose of 786 µL/cm² and finite (darker) dose of 10 µL/cm² of 0.7 % 
active solved in a PGOA formulation were topically applied. Each bar shows the amount of mass per skin layer (SC, E and D) 
and represents the penetration for six replicates (n = 6) from a single donor. Values represent mean ± SD and a total recovery 
of the API > 70 % of the application amount. 
Figure 45 shows the mean amount of caffeine and LIP1 which penetrated in the different skin layers 
for a finite and infinite topical application of a PGOA formulation for 4 h. For both actives and all skin 
layers more active penetrated through the skin when an infinite amount was applied except for the 
LIP1 penetration for a finite amount in the E. Caffeine penetrated into the SC 13-fold, the E 100-fold 
and the D 118-fold significant more and LIP1 penetrated into the SC 2.1-fold and the D 2-fold significant 
more and the E 0.9-fold less. 
6.2.2 Skin penetration using the MD setup  
For the percutaneous skin penetration experiments ex vivo porcine skin was used at room temperature 
with the MD setup and PBS++ as receptor fluid at a flow rate of 3 µL/min. Therefore, the penetration 
of a finite amount (10 µL/cm²) of caffeine or LIP1 from a PGOA formulation into MD membranes 
implanted either superficially or deep in the skin as well as their lateral penetration were tested. 
6.2.2.1 AR of API in the membrane & recovery of API in the membrane for skin saturation 
For a validation of the permeation ability of caffeine and LIP1 inside the MD membrane in a PG and 
PGOA formulation the AR was determined. Therefore, the AR shows the theoretical available amount 
of active which could penetrate through the membrane. To distinguish the skin penetration ability the 
API containing PG and PGOA formulation was injected inside the porcine skin next to the MD 
membrane to test the SR ability. Due to this the maximum realistic amount of active expected by 
penetration through the skin into the membrane is distinguished.  
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Figure 46: Absolute & skin recovery of caffeine. For the AR (A) an infinite amount (1000 μL) of a 0.7 % caffeine in a PG and 
PGOA formulation and the membrane were inserted in a universal tube. For the SR (B) a finite amount (125 µL) of a 0.7 % 
caffeine in a PG and PGOA formulation was injected inside the skin. The mean amount of caffeine over 2 h at room 
temperature was determined every 30 min with a flow rate of 3 μL/min. Each measurement represents the amount of 
caffeine penetrated per mL receptor fluid PBS++ for three replicates (n = 3). Values represent mean ± SD, compared using t-
Test statistics. 
Figure 46 shows the absolute and skin recovered concentration of recovered caffine applied in a PG 
and PGOA formulation. For the PG and PGOA formulation, the AR of caffeine over 2 h shows a linear 
trend and no statistical significant difference in the permeation ability. PGOA shows a caffeine 
permeation range of 412 to 454 µg/mL and PG a 364 to 385 µg/mL. For the PG and PGOA formulation, 
the SR of caffeine over 2 h shows a linear trend and no statistical significant difference in the 
penetration ability. PGOA shows a caffeine penetration range of 48 to 51 µg/mL and PG a 24 to 
45 µg/mL. The ability of caffeine penetration is for PGOA in a AR 8.1-fold higher than for SR and PG is 
8.1-fold higher.  
  
Figure 47: Absolute & Skin recovery of LIP1. For the AR (A) an infinite amount (1000 μL) of a 0.7 % LIP1 in a PG and PGOA 
formulation and the membrane were inserted in a universal tube. For the SR (B) a finite amount (125 µL) of a 0.7 % LIP1 in a 
PG and PGOA formulation was injected inside the skin. The mean amount of LIP1 over 2 h at room temperature was 
determined every 30 min with a flow rate of 3 μL/min. Each measurement represents the amount of LIP1 penetrated per mL 
receptor fluid PBS++ for three replicates (n = 3). Values represent mean ± SD, compared using t-Test statistics. 
A B 
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Figure 47 shows the absolute & skin recovered concentration for LIP1 applied in a PG and PGOA 
formulation. For the PG and PGOA formulation the AR of LIP1 over 2 h shows a linear trend and no 
statistical significant difference in the permeation ability. PGOA shows a LIP1 permeation range of 288 
to 355 µg/mL and PG a 253 to 297 µg/mL. The SR of caffeine shows for the PG and PGOA formulation 
over 2 h a linear trend and no statistical significant difference in the penetration ability. PGOA shows 
a caffeine penetration range of 32 to 34 µg/mL and PG a 32 to 35 µg/mL. The ability of LIP1 penetration 
is for PGOA in a AR 11.1-fold higher than for SR and PG is 8.5-fold higher.  
6.2.2.2 Different penetration depth inside the skin 
 
Figure 48: MD membrane depth inside skin. The depth of a superficial and deep implanted MD membrane inside porcine skin 
was determined using HE, CT and US. Values represent mean ± SD, compared using one-way ANOVA statistics. 
Figure 48 shows the depth of the superficial and deep implanted MD membrane inside porcine skin. 
For the determination of the superficial implanted MD membrane HE, CT and US show a depth of 
294 µm, 380 µm, 338 µm and for the deep implanted a depth of 1199 µm, 1098 µm, and 966 µm. 
Therefore, the superficial depth determination varies 23 % and 20 % for deeply implanted membranes.  
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Figure 49: Caffeine penetration into porcine skin using a superficial implanted MD. A finite amount (10 μL/cm²) of a 0.7 % 
caffeine PGOA formulation was topically applied with a window color fence for three different donors sampled with a 
superficial implanted MD membrane. The mean amount of caffeine over 8 h at room temperature was determined every 
30 min with a flow rate of 3 μL/min. Each measurement represents the amount of caffeine penetrated per mL receptor fluid 
PBS++ for six replicates (n = 6) from a single donor. Values represent mean ± SD, compared using one-way ANOVA statistics. 
Figure 49 shows the amount of caffeine which penetrated inside the porcine skin and was determined 
after sampling from the superficial MD membrane for a finite amount of PGOA formulation for three 
different donors. All three donors show no statistically significant differences for the penetration of 
caffeine inside the skin. A linear increase between 0-6 h reaching a plateau after 8 h is shown and 6.2-
8.4 µg/mL and a difference of 2.2 µg/mL caffeine was detected in the membrane after 8 h. The half of 
the maximum is reached after 3.8 h with 3.8-4.1 µg/mL caffeine and a difference of 0.3 µg/mL. The 
range of the half maximum is 14 % of the maximum variance. The SD of donor 1< donor 2< donor 3. 
 
Figure 50: Caffeine penetration into porcine skin using a deep implanted MD. A finite amount (10 μL/cm²) of a 0.7 % caffeine 
PGOA formulation was topically applied with a window color fence for three different donors sampled with a deep implanted 
MD membrane. The mean amount of caffeine over 8 h at room temperature was determined every 30 min with a flow rate 
of 3 μL/min. Each measurement represents the amount of caffeine penetrated per mL receptor fluid PBS++ for six replicates 
(n = 6) from a single donor. Values represent mean ± SD, compared using one-way ANOVA statistics. 
Figure 50 shows the amount of caffeine which penetrated inside the porcine skin and was determined 
after sampling from the deep implanted MD membrane for a finite PGOA formulation for three 
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different donors. All three donors show no statistically significant differences for the penetration of 
caffeine inside the skin. A linear increase between 2-8 h is shown and 1.4-4.2 µg/cm² caffeine was 
detected in the membrane after 8 h which is a difference of 2.8 µg/mL. The half of the maximum is 
reached after 5 h with 0.5-2 µg/mL caffeine which is a difference of 1.5 µg/mL. The difference of the 
half maximum is 54 % of the maximum variance. The SD of donor 2< donor 1< donor 3. 
 
Figure 51: LIP1 penetration into porcine skin using a superficial implanted MD. A finite amount (10 μL/cm²) of a 0.7 % LIP1 
PGOA formulation was topically applied with a window color fence for three different donors sampled with a superficial 
implanted MD membrane. The mean amount of LIP1 over 8 h at room temperature was determined every 30 min with a flow 
rate of 3 μL/min. Each measurement represents the amount of LIP1 penetrated per mL receptor fluid PBS++ for six replicates 
(n = 6) from a single donor. Values represent mean ± SD, compared using one-way ANOVA statistics. 
Figure 51 shows the amount of LIP1 which penetrated inside the porcine skin and was determined 
after sampling from the superficial implanted MD membrane for a finite PGOA formulation for three 
different donors. All three donors show no statistically significant differences for the penetration of 
LIP1 inside the skin. A linear increase between 2-8 h is seen and 0.78-0.81 µg/cm² LIP1 was detected 
in the membrane after 8 h which is a difference of 0.03 µg/mL. The half of the maximum is reached 
after 5.5 h with 0.41-0.45 µg/mL LIP1 which is a difference of 0.04 µg/mL. The difference of the half 
maximum is 33 % higher than the maximum variance. The SD of donor 3< donor 1< donor 2. 
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Figure 52: LIP1 penetration into porcine skin using a deep implanted MD. A finite amount (10 μL/cm²) of a 0.7 % LIP1 PGOA 
formulation was topically applied with a window color fence for three different donors sampled with a deep implanted MD 
membrane. The mean amount of LIP1 over 8 h at room temperature was determined every 30 min with a flow rate of 
3 μL/min. Each measurement represents the amount of LIP1 penetrated per mL receptor fluid PBS++ for six replicates (n = 6) 
from a single donor. Values represent mean ± SD, compared using one-way ANOVA statistics. 
Figure 52 shows the amount of LIP1 which penetrated inside the porcine skin and was determined 
after sampling from the superficial implanted MD membrane for a finite PGOA formulation for three 
different donors. All three donors show no statistically significant differences for the penetration of 
LIP1. The penetration of LIP1 increased over time and between 0.2-0.36 µg/cm² penetrated the skin in 
a deep MD membrane after 8 h which is a difference of 0.16 µg/mL. The half of the maximum is 
reached after 6 h with 0.1-0.18 µg/mL caffeine which is a difference of 0.08 µg/mL. The difference of 
the half maximum is 50 % of the maximum variance. The SD of donor 3< donor 2< donor 1. 
 
Figure 53: Caffeine penetration into porcine skin using a superficial and deep implanted MD. A finite amount (10μL/cm²) of a 
0.7 % caffeine PGOA formulation was topically applied with a window color fence for three different donors sampled with a 
superficial (dark) and deep (light) implanted MD membrane. The mean amount of caffeine over 8 h at room temperature was 
determined every 30 min with a flow rate of 3 μL/min. Each measurement represents the mean amount of caffeine 
penetrated per mL receptor fluid PBS++ for six replicates (n = 6) for three donors. Values represent mean ± SD, compared 
using one-way ANOVA statistics. 
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Figure 53 shows the mean amount of caffeine which penetrated inside the porcine skin and was 
determined after sampling from the superficial and deep MD membrane for a finite PGOA formulation 
for three donors. A higher amount of caffeine penetrated inside the superficial membrane compared 
to the deep implanted membrane. After 8 h the increasing penetration of caffeine shows a plateau for 
the superficial membrane and an increasing penetration for the deep implanted membrane. After 8 h 
5.4 µg/mL caffeine penetrated inside the superficial and 2.5 µg/mL in the deep implanted membrane 
with a 2.2-fold higher amount. The half of the maximum is reached after 3.1 h whereby the superficial 
membrane shows 4.4-fold higher amount of caffeine. 
 
Figure 54: LIP1 penetration into porcine skin using a superficial and deep implanted MD. A finite amount (10 μL/cm²) of a 
0.7 % LIP1 PGOA formulation was topically applied with a window color fence for three different donors sampled with a 
superficial (dark) and deep (light) implanted MD membrane. The mean amount of LIP1 over 8 h at room temperature was 
determined every 30 min with a flow rate of 3 μL/min. Each measurement represents the mean amount of LIP1 penetrated 
per mL receptor fluid PBS++ for six replicates (n = 6) for three donors. Values represent mean ± SD, compared using one-way 
ANOVA statistics. 
Figure 54 shows the mean amount of LIP1 which penetrated inside porcine skin for three donors and 
was determined after sampling from the superficial and deep MD membrane for a finite PGOA 
formulation. A higher amount of LIP1 penetrated inside the superficial membrane compared to the 
deep implanted membrane. The penetration of LIP1 increased for 8 h and with 0.8 µg/mL after 8 h for 
the superficial and 0.27 µg/mL for the deep membrane, a 3-fold higher amount penetrated in the 
superficial membrane. The half of the maximum is reached after 5.4 h whereby the superficial 
membrane shows with 0.4 µg/mL and the deep implanted membrane with 0.07 µg/mL a 5.7-fold 
higher amount of LIP1. 
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6.2.2.3 Lateral penetration dependent on skin depth 
 
Figure 55: Lateral caffeine penetration into porcine skin using a superficial and deep implanted MD. A finite amount 
(10μL/cm²) of a 0.7 % caffeine PGOA formulation was topically applied with a window color fence for two different donors 
sampled with a superficial and two superficial lateral implanted MD membranes and deep and two deep lateral implanted 
MD membranes. The mean amount of caffeine over 8 h at room temperature was determined every 30 min with a flow rate 
of 3 μL/min. Each measurement represents the mean amount of caffeine penetrated per mL receptor fluid PBS++ for six 
replicates (n = 6) from two donors. Values represent mean ± SD, compared using one-way ANOVA statistics. 
Figure 55 shows the mean amount of caffeine which penetrated inside and laterally the porcine skin. 
The amount of caffeine was determined after sampling from the superficial and deep implanted MD 
membrane for vertical and lateral penetration for a finite PGOA formulation. Increasing amounts of 
caffeine penetrated inside the superficial and deep membranes in the middle of the application area. 
Therefore, the penetration of caffeine in the superficial membrane increases up to a plateau and for 
the deep membrane the amount increases linear with a 1.5-fold higher amount of caffeine inside the 
superficial membrane after 8 h. The half of the maximum is reached after 3.2 h whereby the superficial 
membrane shows with 3.5 µg/mL and the deep implanted membrane with a 1.3 µg/mL a 2.7-fold 
higher amount of caffeine. The relative lateral penetration of caffeine was after 8 h 4.3 % for the 
superficial depth and 7 % for the deep implanted membrane. 
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Figure 56: Lateral caffeine penetration into porcine skin using a deep implanted MD. A finite amount (10 μL/cm²) of a 0.7 % 
caffeine PGOA formulation was topically applied with a window color fence for two different donors sampled with two 
superficial lateral and two deep lateral implanted MD membranes. The mean amount of caffeine over 8 h at room 
temperature was determined every 30 min with a flow rate of 3 μL/min. Each measurement represents the mean amount of 
caffeine penetrated lateral per mL receptor fluid PBS++ for six replicates (n = 6) from two donors. Values represent mean ± 
SD, compared using one-way ANOVA statistics. 
Figure 56 shows the mean amount of caffeine which penetrated laterally the porcine skin inside the 
superficial and deep MD membrane for a finite PGOA formulation. Therefore, the penetration of 
caffeine increased over time and after 8 h 0.32 µg/mL for the superficial and 0.29 µg/mL for the deep 
membrane show a similar amount penetrated laterally the skin. The half of the maximum amount 
which penetrated the skin was reached after 5.8 h. 
 
Figure 57: Lateral LIP1 penetration into porcine skin using a superficial and deep implanted MD. A finite amount (10 μL/cm²) 
of a 0.7 % LIP1 PGOA formulation was topically applied with a window color fence for two different donors sampled with a 
superficial and two superficial lateral implanted MD membranes and deep and two deep lateral implanted MD membranes. 
The mean amount of LIP1 over 8 h at room temperature was determined every 30 min with a flow rate of 3 μL/min. Each 
measurement represents the mean amount of LIP1 penetrated per mL receptor fluid PBS++ for six replicates (n = 6) from two 
donors. Values represent mean ± SD, compared using one-way ANOVA statistics. 
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Figure 57 shows the mean amount of LIP1 which penetrated inside and laterally the porcine skin. The 
amount of LIP1 was determined in the superficial and deep implanted MD membrane for vertical and 
lateral penetration for a finite PGOA formulation. Increasing amounts of LIP1 penetrated inside the 
superficial and deep membranes in the middle of the application area. Increasing amounts of LIP1 
penetrated inside the superficial and deep vertically in the middle of the application area, the amount 
in the superficial membrane increases with a 2.7-fold higher amount after 8 h. The half of the 
maximum is reached after 5.4 h where the superficial membrane shows with 0.8 µg/mL and the deep 
implanted membrane with a 0.25 µg/mL a 2.7-fold higher amount of LIP1. The relative lateral 
penetration of LIP1 was after 8 h 1.3 % for the superficial depth and 3.3 % for the deep implanted 
membrane. 
 
 
Figure 58: Lateral LIP1 penetration into porcine skin using a deep implanted MD. A finite amount (10μL/cm²) of a 0.7 % LIP1 
PGOA formulation was topically applied with a window color fence for two different donors sampled with two superficial 
lateral and two deep lateral implanted MD membranes. The mean amount of LIP1 over 8 h at room temperature was 
determined every 30 min with a flow rate of 3 μL/min. Each measurement represents the mean amount of LIP1 penetrated 
lateral per mL receptor fluid PBS++ for six replicates (n = 6) from two donors. Values represent mean ± SD, compared using 
one-way ANOVA statistics. 
Figure 58 shows the mean amount of LIP1 which penetrated laterally the porcine skin inside the 
superficial and deep MD membrane for a finite PGOA formulation. Therefore, the penetration of LIP1 
increased over time and after 8 h 0.22 µg/mL for the superficial and for the deep membrane show a 
similar amount penetrated laterally the skin. The half of the maximum amount which penetrated the 
skin was reached after 5.4 h. 
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6.2.3 Static lateral penetration  
To test the lateral percutaneous skin penetration ex vivo porcine skin was used at room temperature. 
The penetration features into the E and D of caffeine and LIP1 for a finite amount (10 µL/cm²) of PGOA 
formulation were tested and lateral penetration in E and D were compared to the absolute amount in 
these layers. 
 
  
Figure 59: Lateral and vertical caffeine (A) and LIP1 (B) penetration into different porcine skin layers using a static lateral 
penetration setup. A finite amount (10 μL/cm²) of a 0.7 % active in PGOA formulation was topically applied with a window 
color fence for three different donors. The mean amount of caffeine and LIP1 over 4 h at room temperature which penetrated 
vertical and lateral in the E and D were determined. Each bar represents the mean amount of active penetrated the skin for 
two replicates (n = 2) from three donors. Values represent mean ± SD and a total recovery of the API > 70 % of the application 
amount. 
Figure 59 shows the vertical and lateral penetration of caffeine and LIP1 inside the E and D. The SW for 
caffeine and LIP1 results in 22 µg. For caffeine 7.5 µg penetrated vertically in the E and 12.5 µg in the 
D, the lateral penetration of caffeine shows 0.85 µg in the E and 2.8 µg in the D which is 11.3 % and 
22.4 %. LIP1 penetrated with 5.6 µg vertical in the E and 2.7 µg in the D, the lateral penetration of LIP1 
shows 0.35 µg in the E and 0 µg in the D which is 6.3 % and 0 %. The lateral penetration for caffeine is 
inside the E 2.4-fold higher compared to LIP1. 
A B 
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Figure 60: Lateral and vertical caffeine (A) and LIP1 (B) penetration into porcine skin per skin layer weight using a static lateral 
penetration setup. Lateral and vertical caffeine and LIP1 penetration into different porcine skin layers. A finite amount 
(10 μL/cm²) of a 0.7 % active in PGOA formulation was topically applied with a window color fence for three different donors. 
The mean amount of caffeine and LIP1 over 4 h at room temperature which penetrated vertical and lateral in the E and D 
were determined and are shown per tissue layer weight. Each bar represents the mean amount of active penetrated the skin 
for two replicates (n = 2) from three donors. Values represent mean ± SD and a total recovery of the API > 70 % of the 
application amount. 
Figure 60 shows the vertical and lateral penetration of caffeine and LIP1 per E and D weight. For 
caffeine 0.85 µg/mg penetrated vertical in the E and 0.1 µg/mg in the D, the lateral penetration of 
caffeine shows 0.034 µg/mg in the E and 0.007 µg/mg in the D which is 4 % and 7 % per skin layer 
weight. LIP1 penetrated with 0.73 µg/mg vertically in the E and 0.02 µg/mg in the D, the lateral 
penetration of LIP1 shows 0.016 µg/mg in the E and 0 µg/mg in the D which is 2.2 % and 0 %. The 
lateral penetration for caffeine is inside the E 2.1-fold higher comparted to LIP1. 
A B 
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7 Discussion 
 
Several studies have been conducted to study the dermal and transdermal delivery of drugs through 
the skin in silico, in vitro, ex vivo, and in vivo [38]. In vitro and ex vivo percutaneous penetration studies 
commonly use artificial membranes, porcine skin, and human split-skin as models to verify the 
penetration of topical applied APIs. In addition to external factors, the targeted penetration of active 
ingredients is influenced by the physico-chemical characteristics of the API as well as the formulation. 
Influences on the skin penetration of an active ingredient 
The formulation, formulation volume, active ingredient concentration, temperature, and receptor 
fluid are important for skin penetration. These parameters have been tested for their influence on the 
penetration rate of the model drug caffeine.  
Formulations which are the vehicle of the API, are crucial for their penetration ability; they need to 
dissolve the active ingredient and deliver it to its target-site [69]. Formulations aimed at cosmetic use 
contain multiple ingredients; vehicles for transdermal delivery testing are, in contrast, not as complex. 
Water, PG, OA, and their mixtures are commonly used vehicles in penetration studies [142]. OA was 
shown to increase the penetration of both, hydrophilic and hydrophobic drugs [152]. Most 
formulations are water based, due to this, an understanding of the penetration ability of an aqueous 
vehicle is essential. PG is a component of multiple formulations due to its good solubility characteristics 
and multifunctional use in formulation development; it is well studied and often used in combination 
with fatty acids and penetration enhancers such as OA [143]. For the penetration studies the artificial 
Strat-M® membrane, porcine and human split-skin were used and the penetration characteristics of an 
infinite amount of caffeine in water, PG, or PGOA were tested. PG as a vehicle enhanced the 
penetration ability of the active ingredient more than water as a vehicle (Figure 26). When combined 
with OA, the PGOA formulation showed the highest penetration rate for caffeine. For all human skin 
surrogates, a similar penetration enhancing effect for the water, PG, and PGOA formulations were 
obtained. PG is known to enhance skin penetration by interacting with the polar headgroups of the SC 
lipids, whereas OA enhances the penetration by interacting with the SC lipid alkyl domain, and these 
interactions increases the penetration ability of the API [143]. Designing a formulation exclusively 
based on the physico-chemical solubility properties of the API does not optimize the delivery of the 
API in a cosmetic formulation, and the efficacy of a formulation can be improved by a selection of 
multiple ingredients. The formulation allows to optimize the delivery of active ingredients into the skin 
but it needs to be designed individually for each API. The API diffuses within the formulation to the 
formulation-skin interface and permeates through the lipophilic SC. It diffuses through the hydrophilic 
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E, penetrates into the hydrophilic D, and culminates in delivery to the systemic circulation, which leads 
to systemic absorption. [51] 
Changing the application volume with a constant API concentration increases the penetration rate for 
an increasing volume (Figure 27). The penetration rate of caffeine into porcine skin increased linearly 
with higher application amounts. With the Strat-M® membrane, penetration first increased linearly 
with API volumes less than 100 µL/cm² and then plateaued as the amount of the API administered 
increases. In contrast, the porcine skin showed a linear increase in penetration rate with higher 
application amounts of caffeine (Figure 27). An increasing penetration rate for higher application 
volumes has multiple reasons. Increasing the volume leads to higher skin occlusion, which leads to 
inhibition of skin evaporation and swelling of the SC layer, as well as an increase in the skin 
temperature [3, 21, 147]. This has a direct influence on penetration of the active and deposition, 
affects the degree of hydration of the SC, and enhances penetration via occlusion [153, 154]. The 
concentration gradient, which is the driving force of penetration rate, remains stable long term and 
increases overall penetration [38]. Increasing the application volumes leads to an increased hydrostatic 
pressure, which increases the penetration rate [145]. 
Changing the concentration of topically applied API leads to a change in the concentration gradient 
between the skin surface, inner skin, and the receptor chamber. The concentration gradient drives 
diffusion of active ingredients through the skin [53]. This passive process is described by Fick´s first law 
(Equation 1) and increases with a higher concentration gradient. Figure 28 shows the higher caffeine 
penetration through the Strat-M® membrane and the porcine split-skin with the increase in the active 
concentration inside the formulation. Increasing the concentration of caffeine in the formulation, leads 
to an increase in the caffeine penetration flux [155]. Depending on the molecular properties of the API, 
an up to 300-fold increase in penetration was noted along with an increase in uptake. Depending on 
the degree of saturation of the formulation, different skin layers such as the SC show an 18-fold 
increase in API concentration within those layers [156, 157]. 
Changing the temperature of the percutaneous penetration setup changes the skin uniformity and 
especially the fluidity of the lipids found within the skin [8]. For an infinite amount of caffeine applied 
topically in a PGOA formulation, the penetration rate through the Strat-M® membrane and porcine 
split-skin increased as a result of a higher temperature in the setup (Figure 29). Therefore, a linear 
correlation between the increased penetration rate and temperature is observed for both skin 
surrogates. At room temperature, the main parts of the SC lipids are solid, and with increasing 
temperatures they become more fluid, which leads to an increased penetration rate [8]. Trabaris et al. 
show that the temperature increase from 25°C to 40°C, changes the skin permeability with a 3-fold 
higher penetration flux, in a similar magnitude increase of penetration [148]. 
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By changing the receptor fluid composition of the FDC two main criteria are essential: (1) no alteration 
of the skin integrity, and (2) ensuring the chemical solubility of the API inside the receptor fluid [105]. 
Modified physiological receptor fluids are important to test the penetration of highly lipophilic APIs. 
To have universally receptor fluid for penetration testing of lipophilic and hydrophilic actives, a 
receptor fluid containing multiple additives like albumin, cyclodextrin or the surfactant Brij are used 
[105, 122, 123]. Adding albumin to the receptor fluid is recommended for hydrophilic and lipophilic 
APIs and does not modify the integrity of the skin [105]. Brij as a surfactant has been reported to 
enhance the solubility of hydrophilic and lipophilic drugs [122]. Cyclodextrin is recommended for 
penetration testing of multiple active ingredients and is known to increase the solubility of both 
hydrophilic and lipophilic drugs [123]. Those additives have been used in combination with PBS++ or 
water to test the penetration ability of caffeine [105, 158]. The findings show that caffeine penetrates 
the Strat- M® membrane and porcine split-skin using multiple different receptor fluids, which are 
recommended for lipophilic APIs (Figure 30 and Figure 31). The penetration rate of the hydrophilic 
caffeine was comparable to that of pure PBS++ when albumin, cyclodextrin, and Brij were individually 
added to the receptor fluid. Therefore, those receptor fluids are used for comparing the penetration 
rate of water insoluble lipophilic APIs with the model drug caffeine. To increase the penetration ability 
of APIs, especially caffeine, an optimised vehicle containing the penetration enhancer, in combination 
with a high application volume and high API concentration at 37°C with a suitable receptor fluid is 
necessary.  
Suitable human skin surrogates for percutaneous penetration studies 
For percutaneous penetration testing, in vivo and ex vivo human studies are the most accurate method 
of choice for the prediction of efficient penetration abilities. Due to ethical reasons and limited 
availability of human skin, artificial membranes and ex vivo porcine skin are suitable surrogates for in 
vitro skin studies [44]. To identify the comparability of different in vitro and ex vivo penetration studies, 
the artificial Strat-M® membrane, porcine ear, and human split-skin were compared and tested for 
their penetration ability as human skin surrogates, using caffeine in an FDC penetration setup. 
Therefore, skin integrity, intra- and inter-experimental variations, the impact of kinetic sampling, and 
the influences of penetration enhancers on the penetration rate on different human skin surrogates 
are important. The Strat-M® membrane is a multilayer synthetic membrane that is coated with a SC 
mimicking lipid layer [81]. Porcine ear and human abdomen skin is mostly used for penetration studies 
with a defined dermatomed thickness to achieve reproducible uniformity and predictability; the 
standardized thickness is 500 µm [2]. To validate the thickness of the experimental application area of 
the skin, the peripheral measurement sites were used to determine areas with no statistically 
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significant differences in skin thickness (Figure 18). The integrity of the skin surrogates was determined 
via TEWL; an intra-surrogate uniformity of 20 ± 1, 14 ± 6, and 12.5 ± 3.5 g/m2/h for the Strat-M® 
membrane, porcine, and human skin, respectively, were observed (Figure 19). Therefore, TEWL does 
not allow for a distinction in the permeability of the skin but enables the confirmation of the structural 
integrity of the model used. TEWL is limited in its ability to assess small changes and a decreasing TEWL 
for thicker ex vivo porcine split-skin with a slope of -0.0156 was observed (Figure 20) [159]. In Figure 
21, the experimental variation is shown for all human skin surrogates and the intra-experimental 
variation was found to be larger than the inter-experimental variation (Figure 21 D). The intra-
experimental variation was minimized by the higher number of replicates. Therefore, the minimum of 
four replicates recommended by the OECD was increased to a minimum of six replicates for the 
penetration testing [44]. The inter-experimental variations are shown for the RF as well as for all 
different skin layers for a lipophilic and hydrophilic molecule (Figure 37). The inter-experimental 
variation is described as a donor-specific difference in the skin layers and a difference in penetration 
ability [99]. To better understand the influences of kinetic sampling, individual experiments were 
compared with experimental sampling for every hour or two hours. The inter-experimental differences 
showed a higher impact on the penetration rate of caffeine than the experimental sampling time and 
no significant differences were observed for the human skin surrogates (Figure 22- 24). Similar 
penetration kinetics were observed for caffeine for the Strat-M® membrane and porcine split-skin, with 
a 2.8-fold difference (Figure 25). The findings were comparable to the penetration rate of caffeine 
using human split-skin, with a delay in time and a lower overall penetration flux, which needs to be 
considered when interpreting penetration ability [99]. Testing the penetration ability of different 
caffeine containing formulations, it was found that the penetration enhancing effectbdemonstrates 
the same trend for the different surrogates (Figure 26). The porcine skin showed an overall low 
penetration rate for caffeine, and human skin shows an even lower penetration rate [84, 85, 99, 160]. 
Artificial membranes and especially the Strat-M® membrane support penetration studies and also have 
the potential to help elucidate factors influencing penetration of an API [161, 162]. Porcine ear skin is 
a valuable human skin surrogate owing to its similar skin layer thickness and penetration, providing 
information on the influences on penetration of APIs, with a higher penetration rate than human skin 
[160]. 
Barrier function of the different skin layers 
To study percutaneous penetration, an understanding of the barrier function of SC, E, and D as well as 
the diffusion and penetration ability of hydrophilic and lipophilic molecules in those layers is 
important. The SC as the outer most skin layer, builds a lipophilic environment with an assumed log P 
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of 0.8 [51]. The log P describes the solubility characteristics of an API. To ensure penetration, the API 
needs to be just as much dissolved in the formulation but should not lose its ability to partition into 
the skin. After overcoming the first line of defense, which is the SC, the targeted penetration site could 
be the aqueous E or the D. Lipophilic compounds that overcome the SC barrier, often result in the 
reduction of penetration rates if the more hydrophilic E and D layer is reached [38]. The route of 
penetration an API undertakes after it is topical applied is influenced by absorption from the skin 
surface into the lipophilic SC, followed by subsequent permeation through the more aqueous viable E 
into the aqueous D [38]. APIs with physico-chemical characteristics of a molecular weight lower than 
500 Da and a log P 1-4 are thought to possess good penetration abilities and move through the skin 
layers via passive diffusion [28, 61]. The API caffeine (Log P = -0.1) and LIP1 (Log P = 0.6) with an 
identical molecular weight of 194.19 g/mol but different lipophilic characteristics are ideal for a 
comprehensive comparative penetration study. 
Figure 32 shows the influence of the removal of the SC and E barrier on the penetration of caffeine 
and LIP1 as well as the influence of different D thicknesses on penetration within porcine split-skin. 
The removal of the whole E increases the penetration of both, caffeine and LIP1, with a larger increase 
in penetration rate for caffeine. The removal of the SC had a statistically significant influence on the 
penetration rate of the hydrophilic caffeine, but not for the lipophilic LIP1. With varying D thickness, 
the penetration rate of LIP1 decreases more than that of caffeine, which leads to a linear decrease for 
LIP1 and a plateau for caffeine. Andrews et al. reported that the removal of the SC increases the 
penetration of compounds drastically and the removal of the full E increases this by another 1-2 orders 
of magnitude [163]. Percutaneous penetration experiments measured kinetically with a finite 
application of the API show that skin penetration and diffusion of active ingredients inside the different 
skin layers, to compare the influence of the lipophilicity for the penetration ability. The penetration 
kinetics of caffeine and LIP1 over 1 h, 4 h, and 20 h for a finite formulation of PG and PGOA, show over 
time that caffeine has a higher penetration rate through the skin tissue into the RF than LIP1, but a 
higher amount of active inside the SC, for all time points (Figure 34 and Figure 35). When the E and D 
is reached over time LIP1 shows a higher amount in those layers compared to caffeine, due to a 
reduction of the penetration rates the lipophilic active remains longer in those aqueous layers. 
Comparing in Figure 36 the amount of active inside the skin layers per skin layer weight, LIP1 shows a 
higher skin saturation of all different layers, when measured in a time frame where the active 
ingredient reached those layers. The lipophilic LIP1 shows good penetration potential into the SC, after 
overcoming this barrier, the penetration rate is reduced in the hydrophilic E and D environment and 
the active accumulates in those layers, till it is driven into the RF by the gradient over time. In Figure 
38 the mean percentage per skin layer is shown and is higher in the SC, E and D for LIP1 compared to 
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caffeine. The lipophilic character of APIs supports the penetration through the SC layer and not the 
overall penetration into the skin this needs to be considered by the generalization that APIs with a 
Log P between 1-4 show good penetration abilities [28, 61]. 
Increasing the topical application to an infinite amount of active in a PGOA formulation, increases the 
total amount of caffeine 25-fold and LIP1 9-fold inside the RF (Figure 43). Chen et al. reports the same 
magnitude of penetration increasement by changing the finite to an infinite volume for hydrophilic 
and lipophilic molecules [164]. Figure 44 shows the increasing total amount of active ingredient in all 
skin layers and Figure 45 the increasing amount of active inside the SC, E and D by skin layer weight. 
The amount of caffeine and LIP1 increases inside the SC by increasing the application volume with no 
statistically significant difference between the concentrations measured for caffeine and LIP1 when an 
infinite formulation volume was applied. In contrast the E and D results in an increase inside the tissue 
for caffeine and no statistically difference for LIP1 in those layers for an infinite amount of formulation. 
Herbig et al. reported an increasing amount of active inside the skin layers by increasing the application 
volume for porcine and human skin and the same magnitude of active within the E and D layer per skin 
tissue [165]. 
From the MD experiments with caffeine and LIP1, the AR and SR is higher for the hydrophilic caffeine 
than for the lipophilic LIP1, with a small increase in penetration for caffeine and the SR [166]. The MD 
setup obtains valid experimental data to compare the penetration ability of caffeine and LIP1 into the 
skin and more precise in different D depth [118]. To ascertain the depth of the MD membrane inside 
the skin, the HE staining, US and CT data are compared. The measured depth of the membrane varies 
for all determination methods and the average depth of a superficial implanted membrane ranges 
from 300-500 µm and for a deep implanted from 900-1300 µm. Each of these methods have their own 
advantages and disadvantages making them difficult to compare to each other. So far none of these 
methods has been recognized as the golden standard, and hence it would be most meaningful to select 
a specific method and compare MD membrane implantation depth measurements for a single method. 
The superficial and deep membranes are both implanted in the D layer, but actives which penetrate 
the deep membrane penetrate further through the D layer. Figure 53 shows the concentration of 
caffeine which increases over time, finally resulting in a plateau for penetration into both superficial 
and deep implanted membranes. Figure 54 shows the increase of concentration of LIP1 which 
penetrated into the superficial and deep implanted membrane over time. The half maximum amount 
of penetrated active was reached after 3.1 h for the hydrophilic caffeine and after 5.4 h for the 
lipophilic LIP1. A higher difference of penetration ability for LIP1 compared to caffeine into the 
superficial and deep membrane for the 8 h and half maximum amount are shown. These results 
reinforce the observation that the hydrophilic D environment impacts the penetration of actives and 
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slows down the penetration rate of lipophilic molecules. It was also previously suggested by Koch et 
al. that the permeability of lipophilic molecules is retarded by the diffusional resistance caused by the 
dermal matrix. This retardation of permeation continues till the accumulation of the API results in the 
saturation of the tissue [167]. 
Intra-donor skin equilibrium 
To better understand percutaneous penetration, donor-specific skin layer equilibria and donor 
variation was studied. The SC, E and D are tested for a donor-specific equilibria, using different donors 
for a standard FDC penetration setup as well as a penetration kinetic over 20 h. 
The kinetic caffeine and LIP1 penetration experiments with a finite PGOA formulation show a 
maximum capacity of active in different layers of the skin that was specific to a given donor. Inside the 
E and D there is an intra-donor specific equilibrium which is shown in Figure 36 for caffeine and LIP1. 
Therefore, the same inter trend for an intra equilibrium for both actives are shown for six donors inside 
the E and D for the penetration experiments of 1 h, 4 h and 20 h. The donor-specific variance is shown 
in Figure 37 for three different donors and a 4 h finite topical application penetration experiment of 
caffeine and LIP1 in a PGOA formulation. For caffeine and LIP1 all three donors show an intra-donor 
trend of active concentration inside the SC, E and D layer (Table 5 and Table 6). In Figure 39 the caffeine 
amount in each skin layer normalised to the weight of that layer shows an intra-donor equilibrium of 
each donor and the active in the SC, E and D which varies inter-donor specific. The amount of LIP1 in 
each skin layer normalised to the weight of that layer, confirms the intra-donor equilibrium (Figure 
40). This equilibrium is layer specific which is shown in Figure 45, a saturation stage and an entrapped 
compound reservoir in the different skin layers with a layer depended maximum capacity of a 
hydrophilic and lipophilic compound is observed. The constant flux of API results in a saturation 
concentration per skin layer with a constant in and out flow of active. Herbig et al. reports the same 
magnitude of active within the specific layers per tissue weight [165]. The D appears to accumulate 
the actives until the tissue is saturated and reaches the receptor chamber [167]. The aqueous layers 
incorporate less lipophilic active than the lipophilic skin layer of a hydrophilic or lipophilic active. The 
data supports the assumption of an intra-donor equilibrium which is donor depended, the tissue 
entraps the active till a saturation is reached and enables a further diffusion after. The reservoir 
capacity of the SC is limited and its saturation is dependent on each individual donor, application site, 
substance and formulation [21]. Southwell et al. reported variations of penetration in human skin 
within and between donors but did not observe a donor-specific equilibrium of the different skin layers 
[168]. A schematic illustration of an intra-donor equilibrium and a 1.5-fold higher inter-donor trend 
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(Figure 61).
 
Figure 61: Schematic illustration of the intra-donor equilibrium with an inter-donor difference. Donor 2 shows a 1.5-fold 
higher saturation of active inside the tissue. 
Effect of the lateral penetration inside the skin 
The lipophilic character of an API influences the penetration through and diffusion inside the skin 
depending on the environmental skin layer. Lateral penetration of the hydrophilic caffeine and 
lipophilic LIP1 inside the aqueous E/D layer via the FDC setup and inside D layer via a MD setup and a 
static lateral penetration setup was investigated. For the FDC setup the lateral movement is higher 
over time for caffeine than for LIP1, for a finite topical application in a PG and PGOA formulation (Figure 
34 and Figure 35). In Figure 38 the mean amount of active shows the lateral penetration inside the E/D 
layer for three different donors, with a statistically significant difference between caffeine and LIP1 
and a 1.6-fold higher lateral diffusion for caffeine. The vertical E/D layer shows a saturation of 6 % for 
caffeine and 8 % for LIP1, which leads to an intra E/D increase of the tissue due to the lateral 
penetration of 3-fold for caffeine and 1.5-fold for LIP1. A schematic illustration of the lateral movement 
of caffeine and LIP1 inside the E and D for a FDC setup is shown (Figure 62).  
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Figure 62: Schematic illustration of the lateral penetration of the FDC setup. Caffeine shows a 60 % increase of the lateral 
penetration compared to LIP1. 
The lateral MD setup shows in Figure 55 for the superficial depth 4.3 % lateral penetration and for the 
deep depth 7 % lateral movement of caffeine. By looking at the total amount Figure 56 shows no 
difference between the total lateral penetrated amount, which indicates a conical penetration profile 
with an increasing lateral movement for an increasing penetration depth. Figure 63 illustrates 
schematically an increasing conical lateral movement of caffeine and LIP1 for an increasing skin depth. 
Comparing this with the vertical penetration in Figure 55 the deep implanted membrane should have 
35 % less caffeine than the superficial membrane. LIP1 shows in Figure 56 a lateral penetration of 1.3 % 
for the superficial and 3.3 % for the deep implanted membrane. Figure 57 describes the superficial and 
deep lateral penetration movement of LIP1 and shows no differences on the penetration amount for 
the different depth. Comparing this with the vertical penetration in Figure 56 the deep implanted 
membrane should have 63 % less caffeine than the superficial membrane. The increase of the lateral 
penetration of the deep implanted membrane, in comparison to a superficial membrane for both 
actives, indicates an increasing conical profile movement of the active inside the deeper D layer.  
 Dissertation I Markus Lubda I Discussion  83 
 
Figure 63: Schematic illustration of the lateral penetration of the MD setup. Caffeine shows a 4.3 % and LIP1 1.3 % increase 
for lateral penetration for the superficial depth and a 7 % and 3.3 % increase for the deep depth. 
The static lateral penetration setup shows in Figure 59 for caffeine a relative lateral diffusion inside the 
E of 11.3 % and in the D a 22.4% of the recovered amount per E and D layer. LIP1 shows 6.3 % of relative 
lateral movement inside the E and 0 % of relative lateral movement of the recovered amount of the E 
and D layer. Comparing this with the amount found per weight of skin layer Figure 60 shows for 
caffeine a 4 % and 7 % of relative lateral penetration for E and D and for LIP1 2.2 % and 0 %. Overall 
caffeine showed a higher lateral diffusion characteristic than LIP1, due to the hydrophilic skin 
environment the lateral movement of LIP1 is reduced as well as the lateral conical movement inside 
further lateral tissue. Nguyen et al. showed a contribution of lateral movement of actives inside the D 
as contribution to the overall penetration [78]. Lateral spreading or diffusion was investigated for the 
SC layer, but a lateral penetration inside this and other layers is still not fully understood [77, 169, 170].  
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8 Outlook 
For a further understanding how the lipophilic characteristics of an API influences the penetration 
ability, a diverse set of molecules with a log P ranging -2 to 5 need to be tested for their percutaneous 
penetration ability.  
Currently, API efficacy testing as a proof of principle is accomplished via 2D cell culture and 
distinguishes the minimum concentration needed to achieve a desired biological response. This needs 
to be cross validated with the penetration ability of the API and if the minimum amount of active 
ingredient can be located at its target-site. Due to a lack of blood vessels, connection and 
communication of cells using assays are not predictive for viable skin. The minimally invasive MD 
penetration system enables a double read out for ex vivo skin, with penetration ability controlled via 
a skin response. The skin reactions are monitored in situ on the basis of its metabolites and their 
utilization as beneficial novel active ingredients.  
However, HPLC is not sensitive enough to distinguish the API concentration for beneficial MD analysis 
and needs to be coupled with mass spectrometry to enable API detection in smaller volumes. This 
would enable more frequent sampling, leading to more accurate kinetic analysis which would in turn 
help in the interpretation of data for active ingredients with low penetration ability. Those in vitro and 
ex vivo assays give information about the API penetration ability and biological response, but the 
absence of the cutaneous metabolism, blood circulation and the possible physiological changes which 
will take place after excision are limiting factors [112].  
To overcome this, animal in vivo penetration studies of molecules with diverse lipophilic characteristics 
would provide information regarding target-site penetration and the biological response. But for an 
understanding of the penetration ability and the desired biological effect of active ingredients inside 
the human skin, percutaneous human in vivo clinical studies are essential. Therefore, the penetration 
ability of APIs and their biological effect are studied in parallel and the systemic uptake can be 
determined. This setup has the drawback of no direct correlation between the site of application and 
API distribution inside the tissue [112]. A combination of in vitro, ex vivo, and in vivo analyses of 
artificial membranes, porcine skin, and human skin, provides the most reliable percutaneous 
penetration data for APIs in terms of biological uptake and function. 
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9 Executive summary 
The aim of this study was to understand target-site penetration and the influence of lipophilicity on 
the penetration of the API by analyzing the penetration of hydrophilic caffeine and lipophilic LIP1 in 
porcine skin. Target-site penetration is of interest to determine the functionality of active compounds 
and to understand overall skin penetration. Therefore, in vitro and ex vivo FDC and MD penetration 
setups were used in combination with the Strat-M® membrane, porcine ear skin, and human skin as 
surrogate methods for in vivo human testing. The selection of the penetration model, skin surrogate, 
APIs, dosing amount and RF need to be based on the research question being addressed. 
Thereby multiple factors influence the penetration ability, to increase the penetration of APIs an 
optimised vehicle, containing penetration enhancer are used. In combination with a high application 
volume and API concentration at high penetration temperature the penetration rate is increased and 
optimised.  
Artificial membranes and especially the Strat-M® membrane support penetration studies, and also 
have the potential of predicting to help elucidate the influences on penetration [161, 162]. Porcine ear 
skin is a valuable human skin surrogate, providing information on the influences on penetration of 
APIs, but its higher penetration rate than human skin also needs to be taken into account. 
The skin is build up of multiple layers, the SC provides a lipophilic barrier for the penetration of APIs, 
followed by the hydrophilic E and D environment. Lipophilic APIs like LIP1 show a good penetration 
potential into the SC, by overcoming this barrier, the penetration rate is reduced by the hydrophilic E 
and D environment and the active accumulates in those layers, till the kinetic and gradient drive the 
active into the RF. These results reinforce the observation that the lipophilic SC, and the hydrophilic E 
and D environment impacts the penetration of active ingredients into skin. The lipophilic environment 
slows down the penetration rate of hydrophilic molecules and the hydrophilic environment slows 
down the rate of lipophilic active ingredients. 
For caffeine and LIP1, different donors show an intra-donor trend of active ingredient concentration 
inside the SC, E, and D layer. Each donor shows an intra-donor equilibrium of active ingredient in the 
SC, E, and D which varies within donors. This equilibrium is layer specific and an entrapped compound 
reservoir in the different skin layers, along with a layer dependent maximum capacity of a hydrophilic 
and lipophilic compound is observed. The aqueous skin layers incorporate less lipophilic active 
ingredient than the lipophilic skin layer for hydrophilic or lipophilic active ingredients.  
The lateral penetration studies indicated a conical penetration profile in the presence of increasing 
lateral movement with increasing penetration depth. The increase in lateral penetration for deep 
implanted membranes, in comparison to a superficial membrane for both active ingredients, indicates 
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an increasing conical movement of active ingredients inside the deeper D layer. Overall, caffeine 
showed higher lateral diffusion than LIP1 did; due to the hydrophilic skin environment, the lateral 
movement of LIP1 is reduced as well as the lateral conical movement further inside lateral tissue. 
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10 Appendix 
 Abbreviations 
® registered trademark 
°C degree Celsius 
μg Microgram 
µL Microliter 
mL Milliliter 
nm Nanometer 
µm Micrometer 
mm Millimetre 
Da Dalton 
kDa Kilodalton 
min Minute 
h Hour 
mA Milliamper 
Milli-Q water Pure water 
PG Propylene glycol 
OA Oleic acid 
PBS Phosphate buffered saline 
PBS++ Phosphate buffered saline, with Mg2+ and Ca2+ 
PBS-- Phosphate buffered saline, without Mg2+ and Ca2+ 
BSA Bovine Serum Albumin 
CD Cyclodextrin 
B Brij O20 
SC Stratum Corneum 
E Viable epidermis 
D Dermis 
SEM Scanning Electron Microscope 
CT Computer Tomography 
HPLC High-performance liquid chromatography 
MD Microdialysis 
AR Absolute recovery 
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SR Skin recovery 
FDC Franz Diffusion Cell 
OECD Organization for Economic Cooperation and Development 
SCCS Scientific Committee on Consumer Safety 
SD Standard Deviation  
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